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SCIENTIFIC OPINION
Scientific Opinion on Flavouring Group Evaluation 78, Revision 2
(FGE.78Rev2): Consideration of aliphatic and alicyclic and aromatic
hydrocarbons evaluated by JECFA (63rd meeting) structurally related to
aliphatic hydrocarbons evaluated by EFSA in FGE.25Rev3 0F1
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
(CEF)2,3
European Food Safety Authority (EFSA), Parma, Italy
ABSTRACT
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety
Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint
FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide whether further evaluation is
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The present consideration concerns 21
aromatic, aliphatic and alicyclic hydrocarbons [FL-no: 01.002, 01.003, 01.004, 01.005, 01.006, 01.007, 01.008,
01.009, 01.010, 01.016, 01.017, 01.018, 01.019, 01.020, 01.024, 01.026, 01.029, 01.040, 01.045, 01.061 and
01.077] evaluated by the JECFA in 2005. FGE.78Rev1 considered 24 substances, but 4-methyl-1,1'-biphenyl
(JECFA-no: 1334) and biphenyl (JECFA-no: 1332) [former FL-no: 01.011 and 01.013] are no longer supported
by Industry for use as a flavouring substance in Europe. Moreover 1-methylnaphthalene [FL-no: 01.014] is in the
process of being deleted from the Union List. This revision is owing to additional genotoxicity data on β-
caryophyllene [FL-no: 01.007] and 90-day studies in rats on β-caryophyllene [FL-no: 01.007] and myrcene [FL-
no: 01.008]. The substances were evaluated through a stepwise approach that integrates information on structure-
activity relationships, intake from current uses, toxicological threshold of concern, and available data on
metabolism and toxicity. The specifications for the materials of commerce are adequate for all substances. The
Panel concluded that the 21 aromatic, aliphatic and alicyclic hydrocarbons [FL-no: 01.002-01.010, 01.016-
01.020, 01.024, 01.026, 01.029, 01.040, 01.045, 01.061 and 01.077] do not give rise to safety concern at their
levels of dietary intake, estimated on the basis of the MSDI approach.
© European Food Safety Authority, 2015
1 On request from the European Commission, Question No EFSA-Q-2013-00185 to -00192 and EFSA-Q-2013-00845 to
-00848, adopted on 18 March 2015.
2 Panel members: Claudia Bolognesi, Laurence Castle, Jean-Pierre Cravedi, Karl-Heinz Engel, Paul Fowler, Konrad Grob,
Rainer Gürtler, Trine Husøy, Wim Mennes, Maria Rosaria Milana, André Penninks, Maria de Fatima Tavares Poças,
Vittorio Silano, Andrew Smith, Christina Tlustos, Fidel Toldra, Detlef Wölfle and Holger Zorn. Correspondence:
fip@efsa.europa.eu
3 Acknowledgement: The Panel wishes to thank the members of the Working Groups on Flavourings: Ulla Beckman Sundh,
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preparatory work on this scientific opinion and the hearing experts: Vibe Beltoft and Karin Nørby and EFSA staff:
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SUMMARY
Following a request from the European Commission the EFSA Panel on Food Contact Materials,
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver scientific opinion on the
implications for human health of chemically defined flavouring substances used in or on foodstuffs in
the Member States. In particular, the CEF Panel was requested to consider the Joint FAO/WHO
Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances assessed since
2000, and to decide whether no further evaluation is necessary, as laid down in Commission
Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, which was
adopted by Commission Decision 1999/217/EC and its consecutive amendments.
The present revision of FGE.78, FGE.78Rev2, includes the assessment of additional available toxicity
data for β-caryophyllene [FL-no: 01.007] and myrcene [FL-no: 01.008]. The data provided are for 
both substances a new 90-day study. Furthermore, new short term study and genotoxicity data have
been provided for [FL-no: 01.007]. In addition, since the publication of FGE.78Rev1, two ([FL-no:
01.011 and 01.013]) of the 24 substances are no longer supported for use as flavouring substances in
Europe by Industry. Moreover, [FL-no: 01.014] is in the process of being deleted from the Union List.
Accordingly, FGE.78Rev2 only deals with 21 substances.
The Panel concluded that the 21 substances in the JECFA flavouring groups of aliphatic and alicyclic
and aromatic hydrocarbons are structurally related to the group of 14 aliphatic hydrocarbons evaluated
by EFSA in the Flavouring Group Evaluation 25, Revision 3 (FGE.25Rev3).
The Panel agrees with the application of the Procedure as performed by the JECFA for eight of the 21
substances considered in this FGE [FL-no: 01.002, 01.005, 01.006, 01.016, 01.019, 01.020, 01.045
and 01.077].
For the following 13 substances [FL-no: 01.003, 01.004, 01.007, 01.008, 01.009, 01.010, 01.017,
01.018, 01.024, 01.026, 01.029, 01.040 and 01.061] it cannot be concluded that they are metabolised
to innocuous substances and therefore their evaluation should proceed along the B-side of the
Procedure. For one of these substances, 1-isopropenyl-4-methylbenzene [FL-no: 01.010] from
subgroup IVe (alkyl substituted benzene hydrocarbons), a NOAEL was available giving an adequate
margin of safety compared to the estimated level of intake.
For eight substances [FL-no: 01.003, 01.004, 01.007, 01.009, 01.017, 01.024, 01.026 and 01.029]
adequate margins of safety compared to the estimated levels of intake were estimated based upon a
NOAEL from a 90-day study in rats, for the representative substance ß-caryophyllene [FL-no:
01.007]. The NOAEL of 222 mg/kg bw per day provides a margin of safety of 40 000 for ß-
caryophyllene. The margins of safety for [FL-no: 01.003, 01.004, 01.009, 01.017, 01.024, 01.026 and
01.029] based upon the respective MSDI for these substances and the NOAEL for ß-caryophyllene,
range between 7400 and 1.1x107. The Panel agrees that this provides sufficient safety margins and that
these flavouring substances can be evaluated at step B4 in the Procedure as being of no safety concern.
For four substances [FL-no: 01.008, 01.018, 01.040 and 01.061] adequate margins of safety compared
to the estimated levels of intake were estimated based upon a NOAEL from a 90-day study in rats, for
the representative substance myrcene [FL-no: 01.008]. The NOAEL of 44 mg/kg bw per day provides
a margin of safety of 9100 for myrcene. The margins of safety for [FL-no 01.018, 01.040 and 01.061]
based upon the respective MSDI for these substances and the NOAEL for myrcene are 4.8x105,
4.4x106 and 1.1x107, respectively. The Panel agrees that this provides sufficient safety margins and
that these flavouring substances can be evaluated at step B4 in the Procedure as being of no safety
concern.
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For four substances use levels have been provided by the Industry [FL-no: 01.008, 01.011, 01.013 and
01.026] and the mTAMDI have been considered. The mTAMDI figures calculated were above the
threshold of concern for all four substances and more reliable exposure data are needed. On the basis
of such additional data these flavouring substances should be reconsidered using the Procedure. For
the remaining 17 substances evaluated through the Procedure use levels are needed to calculate the
mTAMDIs in order to identify those flavouring substances that need more refined exposure
assessment to finalise the evaluation.
In order to determine whether the conclusion for the 21 JECFA evaluated substances can be applied to
the materials of commerce, it is necessary to consider the available specifications.
Adequate specifications including complete purity criteria and identity are available for all 21 JECFA
evaluated substances.
Thus, for the 21 substances4 [FL-no: 01.002, 01.003, 01.004, 01.005, 01.006, 01.007, 01.008, 01.009,
01.010, 01.016, 01.017, 01.018, 01.019, 01.020, 01.024, 01.026, 01.029, 01.040, 01.045, 01.061 and
01.077] the Panel agrees with the JECFA conclusion “no safety concern at estimated levels of intake
as flavouring substances” based on the MSDI approach.
4 The 22nd substance, 1-methylnaphthalene [FL-no: 01.014] is in the process of being deleted from the Union List (DG
SANTE, 2015).
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION
The use of flavourings in food is regulated under Regulation (EC) No 1334/2008 of the European
Parliament and Council of 16 December 20085 on flavourings and certain food ingredients with
flavouring properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an
evaluation and approval are required for flavouring substances.
The Union list of flavourings and source materials was established by Commission Implementing
Regulation (EC) No 872/20126. The list contains flavouring substances for which the scientific
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/20007.
FGE.78Rev1
On 19 May 2011, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing
Aids (CEF) adopted an opinion on Flavouring Group Evaluation 78, Revision 1 (FGE.78Rev1):
Consideration of aliphatic and alicyclic and aromatic hydrocarbons evaluated by JECFA (63rd
meeting) structurally related to aliphatic and aromatic hydrocarbons evaluated by EFSA in
FGE.25Rev28.
The substances [FL-no: 01.008, 01.018, 01.040 and 01.061] were among the 14 substances for which
the Panel had “reservations (no European production volumes available, preventing them from being
evaluated using the Procedure, and/or missing information on stereoisomerism/composition of
mixture)” and also among those for which “additional toxicity data was requested”.
FGE.25Rev2
On 19 May 2011, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing
Aids (CEF) adopted an opinion on Flavouring Group Evaluation 25, Revision 2 (FGE.25Rev2):
Aliphatic and aromatic hydrocarbons from chemical group 319.
The substances with [FL-no: 01.035, 01.064, 01.070 and 01.035] were among the 27 candidate
substances for which “additional toxicity data” were required by EFSA. For [FL-no: 01.035] also
“additional information on composition” was requested.
FGE.18Rev2
On 30 September 2010, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids (CEF) adopted an opinion on Flavouring Group Evaluation 18, Revision 2
(FGE.18Rev2): Aliphatic, alicyclic and aromatic saturated and unsaturated tertiary alcohols, aromatic
tertiary alcohols and their esters from chemical groups 6 and 8.
For the flavouring substance [FL-no: 02.146], the Panel considered that “additional data” are needed
including “information on specifications/stereoisomerism/composition of mixture”.
5 Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50.
6 Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC)
No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p. 1-161.
7 Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16.
8 EFSA Journal 2011;9(6):2178
9 EFSA Journal 2011;9(6):2177
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On 21 November 2012, the EFSA Panel on Food Contact Materials, Enzymes, Flavourings and
Processing Aids (CEF) adopted a statement on the re-evaluation of 3,7-dimethylocta-1,5,7-trien-3-ol
[FL-no: 02.146] based on additional data on a supporting substance10.
The Panel concluded that “linalool [FL-no: 02.013] is not sufficiently structurally related to 3,7-
dimethylocta-1,5,7-trien-3-ol [FL-no: 02.146] for a re-evaluation of [FL-no: 02.146]”. Accordingly, “a
90-day study on 3,7- dimethylocta-1,5,7-trien-3-ol [FL-no: 02.146] or on a sufficiently structurally
related substance has to be provided in order to establish on appropriate NOAEL”.
New data and relationship with other substances
On 5 and 11 July 2013, the applicant submitted additional data on the following acyclic terpene
hydrocarbons [FL-no: 01.008, 01.018, 01.040, 01.061, 01.035, 01.064, 01.070 and 02.146, represented
by myrcene [FL-no: 01.008].
As regards the related substances also evaluated in these opinions, namely [FL-no: 01.003, 01.004,
01.007, 01.009, 01.017, 01.024, 01.026, 01.029 and 01.059], data was submitted and are currently
being evaluated (EFSA-Q-2013-00185 to – 00193).
As regards substance with [FL-no: 01.014], data should be submitted by 31 December 201311.
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION
The European Commission requests the European Food Safety Authority (EFSA) to finalise its safety
assessment on this group of flavouring substances in accordance with Commission Regulation (EC)
No 1565/2000.
SUPPORTING DOCUMENTS
Submission by the European Flavour Association
INTERPRETATION OF THE TERMS OF REFERENCE
The above background and terms of reference include also a previous mandate received from the
European Commission on 6 February 201312. The present scientific opinion FGE.78Rev2 covers the
safety assessment of the following flavouring substances: Pin-2(10)-ene with [FL-no: 01.003], Pin-
2(3)-ene with [FL-no: 01.004], beta-caryophyllene with [FL-no: 01.007], Camphene with [FL-no:
01.009], Valencene with [FL-no: 01.017], beta-Bourbonene with [FL-no: 01.024], 1(5),7(11)-
Guaiadiene with [FL-no: 01.026], delta-3-Carene [FL-no: 01.029], Myrcene with [FL-no: 01.008],
beta-Ocimene with [FL-no: 01.018], alpha-Farnesene with [FL-no: 01.040] and Undeca-1,3,5-triene
with [FL-no: 01.061].
10 EFSA Journal 2012;10(12):2995
11 This substance is in the process of being deleted from the Union List (DG SANTE, 2015)
12 SANCO.E3/SH/km D (2013) Ares(2013)15188
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ASSESSMENT
The approach used by EFSA for safety evaluation of flavouring substances is referred to in
Commission Regulation (EC) No 1565/2000, hereafter named the “EFSA Procedure”. This Procedure
is based on the opinion of the Scientific Committee on Food (SCF, 1999), which has been derived
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA
Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the
Panel) compares the JECFA evaluation of structurally related substances with the result of a
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data,
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring
substances are of no safety concern at their estimated levels of intake, whether additional data are
required or whether certain substances should not be evaluated through the EFSA Procedure.
The following issues are of special importance.
Intake
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI)
approach to estimate the per capita intakes of the flavouring substances in Europe.
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both
European and USA production figures. The highest of the two MSDI figures is used in the evaluation
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available,
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of
these figures. For Register substances, for which this is the case, the Panel will need EU production
figures in order to finalise the evaluation.
When the Panel examined the information provided by the European Flavour Industry on the use
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would
grossly underestimate the intake by regular consumers of products flavoured at the use level reported
by the Industry, especially in those cases where the annual production values were reported to be
small. In consequence, the Panel had reservations about the data on use and use levels provided and
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65th meeting
considered “how to improve the identification and assessment of flavouring agents, for which the
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from
the anticipated average use levels in foods” (JECFA, 2006b).
In the absence of more accurate information that would enable the Panel to make a more realistic
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake
(mTAMDI) approach based on the normal use levels reported by Industry.
As information on use levels for the flavouring substances has not been requested by the JECFA or
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on
use levels in order to finalise the evaluation.
Threshold of 1.5 Microgram/Person per day (Step B5) Used by the JECFA
The JECFA uses the threshold of concern of 1.5 microgram (µg)/person per day as part of the
evaluation procedure:
“The Committee noted that this value was based on a risk analysis of known carcinogens which
involved several conservative assumptions. The use of this value was supported by additional
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information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the
Committee, flavouring substances for which insufficient data are available for them to be evaluated
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per
day would not be expected to present a safety concern. The Committee recommended that the
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended
to include the last step on the right-hand side of the original procedure (“Do the condition of use result
in an intake greater than 1.5 µg per day?”)” (JECFA, 1999).
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does
not make use of this threshold of 1.5 µg per person per day.
Genotoxicity
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible
genotoxic potential of the flavouring substances or of structurally related substances. Generally,
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro,
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided.
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through
the Procedure.
Specifications
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of
JECFA, since the Panel requests information on e.g. isomerism.
Structural Relationship
In the consideration of the JECFA evaluated substances, the Panel will examine the structural
relationship and metabolism features of the substances within the flavouring group and compare this
with the corresponding FGE.
1. History of the Evaluation of the Substances in the Present FGE
At its 63rd meeting the JECFA evaluated a group of 20 flavouring substances consisting of aliphatic
and alicyclic hydrocarbons and another group of five aromatic hydrocarbons (JECFA, 2006a). One of
the substances, d-limonene ([FL-no: 01.045], JECFA-no: 1326), was at the 39th meeting allocated an
acceptable daily intake (ADI) of 0 - 1.5 mg/kg body weight (bw). This ADI was withdrawn at the 41st
meeting and replaced by an “ADI not specified”. One of the substances in the group of aliphatic and
alicyclic hydrocarbons is not in the Register (cadinene – mixture of isomers, JECFA-no: 1346).
FGE.78 therefore dealt with 24 JECFA evaluated aliphatic, alicyclic and aromatic hydrocarbons
(EFSA, 2009).
The Revision 1 of FGE.78, FGE.78Rev1, concerned the re-consideration of one JECFA evaluated
substance considered in FGE.78. In FGE.78, the Panel concluded that for 13 substances no applicable
NOAEL was available for the substance itself or on a structurally related compound and therefore
further data were required. Additional data (long term study of toxicity, mutagenicity studies and new
tonnage figure) became available for myrcene [FL-no: 01.008] and the FGE.78Rev1 included the
evaluation of these data submitted by the Industry (Flavour Industry, 2010). Furthermore, after
publication of FGE.78, the JECFA re-evaluated flavouring substances for which new tonnage data
were submitted to the JECFA by Industry. These tonnage figures were included in FGE.78Rev1 for
[FL-no: 01.029 and 01.040] (EFSA CEF Panel, 2011a).
Since the publication of FGE.78Rev1, [FL-no: 01.011, 01.013 and 01.014] are no longer supported for
use as flavouring substances in Europe by Industry (DG SANCO, 2012 and DG SANTE, 2015) and
will therefore not be considered any further in the present FGE. For this, the three listed below
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substances will be excluded from this revision except in tables 3 and 11. Information in the text on
these substances will be kept only if relevant for the remaining substances.
FL-no
JECFA-no
EU Register name
01.011
1334
4-Methyl-1,1'-biphenyl
01.013
1332
Biphenyl
01.014 1-Methyl-naphthalene
Accordingly, FGE.78Rev2 deals with 21 substances.
The table below gives information on publication dates and links to the published versions.
FGE Opinion
adopted by
EFSA
Link No. of candidate
substances
78 6 March 2008 http://www.efsa.europa.eu/en/scdocs/scdoc/931.htm 24
78Rev1 18 May 2011 http://www.efsa.europa.eu/en/efsajournal/pub/2178.htm 24
78Rev2 18 March 2015 21
The present revision of FGE.78, FGE.78Rev2, includes additional toxicity data provided for two
representative substances β-caryophyllene [FL-no: 01.007] and myrcene [FL-no: 01.008]. β-
Caryophyllene [FL-no: 01.007] has been selected as representative substance for pin-2(10)-ene [FL-
no: 01.003], pin-2(3)-ene [FL-no: 01.004], camphene [FL-no: 01.009], valencene [FL-no: 01.017], β-
bourbonene [FL-no: 01.024], 1(5),7(11)-guaiadiene [FL-no: 01.026] and δ-3-carene [FL-no: 01.029]. 
Myrcene [FL-no: 01.008] has been selected as representative substance for β-ocimene [FL-no: 
01.018], α-farnesene [FL-no: 01.040] and undeca-1,3,5-triene [FL-no: 01.061] (EFSA CEF Panel, 
2012). The data provided are for each of the two representatives a 90-day study. Furthermore, a new
short term study and genotoxicity data have been provided for [FL-no: 01.007] (EFFA, 2012). A
search in open literature was conducted for genotoxicity for the two representative substances β-
caryophyllene [FL-no: 01.007] and myrcene [FL-no: 01.008]. This search did not reveal any pertinent
new information on the substances.
Information on isomerism or on composition of mixture had been provided for 14 substances [FL-no:
01.004, 01.007, 01.008, 01.009, 01.017, 01.018, 01.019, 01.020, 01.024, 01.026, 01.029, 01.040,
01.045 and 01.061] (EFFA, 2013; EFFA, 2015) and EU production volume has been provided for one
substance [FL-no: 01.024] (EFFA, 2012) since the previous evaluation of FGE.78.
2. Presentation of the Substances in the JECFA Flavouring Group
2.1. Description
2.1.1. JECFA Status
The JECFA has evaluated two groups of flavouring substances at their 63rd meeting:
• a group of 20 substances consisting of aliphatic and alicyclic hydrocarbons
• a group of five aromatic hydrocarbons
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One of the substances, d-limonene ([FL-no: 01.045], JECFA-no: 1326), was at the 39th meeting
allocated an acceptable daily intake (ADI) of 0-1.5 mg/kg body weight (bw). This ADI was withdrawn
at the 41st meeting and replaced by an “ADI not specified”.
One of the substances in the group of aliphatic and alicyclic hydrocarbons is not in the Register
(cadinene – mixture of isomers, JECFA-no: 1346). Three substances, 4-methyl-1,1'-biphenyl (JECFA-
no: 1334), biphenyl (JECFA-no: 1332) and 1-methylnaphthalene [former FL-no: 01.011, 01.013 and
01.014] are no longer supported for use as flavouring substances in Europe by Industry. This
consideration will therefore deal with 21 JECFA evaluated aliphatic, alicyclic and aromatic
hydrocarbons.
2.1.2. EFSA Considerations
The Panel concluded that the 21 substances in the JECFA flavouring group of aliphatic, alicyclic and
aromatic hydrocarbons are structurally related to the group of aliphatic hydrocarbons evaluated by
EFSA in the Flavouring Group Evaluation 25, Revision 3 (FGE.25Rev3).
Because of the structural diversity within this group, EFSA subdivided the substances considered in
FGE.25Rev3 into subgroups. For the sake of clarity and consistency, the substances evaluated
previously by the JECFA which are considered in the present evaluation have been allocated to the
corresponding subgroups. The subgrouping is shown in Table 4 in Section 6.3.
2.2. Isomers
2.2.1. Status
The following 10 substances [FL-no: 01.003, 01.004, 01.006, 01.007, 01.009, 01.017, 01.024, 01.026,
01.029 and 01.045] in the group of 21 JECFA evaluated aliphatic, alicyclic and aromatic hydrocarbons
have one or more chiral centres and the following three [FL-no: 01.018, 01.040 and 01.061] can exist
as geometrical and/or other isomers.
2.2.2. EFSA Considerations
Adequate information on isomerism and composition data has been provided for all these substances.
2.3. Specifications
2.3.1. Status
The JECFA specifications are available for all 21 substances (JECFA, 2005a) (see Table 3).
2.3.2. EFSA Considerations
The available specifications are considered adequate for all 21 substances (see Section 2.2.1).
3. Intake Estimation
3.1. Status
For all substances evaluated through the JECFA Procedure, EU production volumes are available (see
Table 11).
3.2. EFSA Considerations
Only for two of the 21 JECFA evaluated substances normal and maximum use levels have been
provided by the Flavour Industry (EFFA, 2005) (see Table 2). Based on these normal use levels, the
intakes based on mTAMDI (see Table 1) can be calculated (EC, 2000; EFSA, 2004).
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Table 1: Estimated Intakes Based on the MSDI- and the mTAMDI Approach – FGE.78Rev2
FL-no EU Register name MSDI – EU
(µg/capita per
day)
MSDI – USA
(µg/capita per
day)
mTAMDI
(µg/person per
day)
Structural
class
Threshold of concern
(µg/person per day)
01.002 1-Isopropyl-4-methylbenzene 926 472 Class I 1800
01.003 Pin-2(10)-ene 1300 759 Class I 1800
01.005 Terpinolene 660 70 Class I 1800
01.006 alpha-Phellandrene 79 410 Class I 1800
01.007 beta-Caryophyllene 330 508 Class I 1800
01.009 Camphene 13 28 Class I 1800
01.010 1-Isopropenyl-4-methylbenzene 18 0.3 Class I 1800
01.016 1,4(8),12-Bisabolatriene 13 10 Class I 1800
01.017 Valencene 53 26 Class I 1800
01.018 beta-Ocimene 55 11 Class I 1800
01.019 alpha-Terpinene 28 93 Class I 1800
01.020 gamma-Terpinene 1200 321 Class I 1800
01.024 beta-Bourbonene 0.012 0.2 Class I 1800
01.026 1(5),7(11)-Guaiadiene 0.012 3 3900 Class I 1800
01.029 delta-3-Carene 290 40 Class I 1800
01.040 alpha-Farnesene 0.61 40 Class I 1800
01.061 Undeca-1,3,5-triene 0.24 0.2 Class I 1800
01.077 1-Methyl-1,3-cyclohexadiene 0.012 313 Class I 1800
01.004 Pin-2(3)-ene 1800 2444 Class I 1800
01.008 Myrcene 290 153 3900 Class I 1800
01.045 d-Limonene 34000 12726 Class I 1800
Flavouring Group Evaluation 78 Revision 2
EFSA Journal 2015;13(4):4067 14
Table 2: Normal and Maximum Use Levels (mg/kg) Available for JECFA evaluated Substances in FGE.78Rev2
FL-no Food Categories
Normal use levels (mg/kg)
Maximum use levels (mg/kg)
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0
01.008 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
01.026 7
35
5
25
10
50
7
35
-
-
10
50
5
25
10
50
2
10
2
10
-
-
-
-
5
25
10
50
5
25
10
50
20
100
5
25
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SUMMARY OF SPECIFICATION DATA
Table 3: Specifications Summary for the JECFA Evaluated Substances in the Present Group (JECFA, 2005a)
FL-no
JECFA
-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index
(d)
Spec.gravity
(e)
EFSA comments
01.002
1325
1-Isopropyl-4-
methylbenzene
2356
620
99-87-6
Liquid
C10H14
134.21
Insoluble
Soluble
177
IR
97 %
1.484-1.491
0.853-0.855
01.003
1330
Pin-2(10)-ene 2903
2114
127-91-3
Liquid
C10H16
136.24
Insoluble
Insoluble
163-166
NMR
97 %
1.476-1.482
0.867-0.871 Racemate.
01.004
1329
Pin-2(3)-ene 2902
2113
80-56-8
Liquid
C10H16
136.24
Insoluble
Soluble
155
NMR
97 %
1.462-1.468
0.855-0.860 Racemate. According to
the JECFA: ”Min. assay
value may include
traces of limonene, ß-
pinene and other
common C10H16
terpenes”. The traces
are 1-3 % limonene
(racemate), 1-3 % β-
pinene (racemate) and
1-3 % other ”common
terpenes” (α-terpinene, 
β-terpinene, δ-3-carene, 
terpinolene etc (each <
1 %)) (EFFA, 2015).
01.005
1331
Terpinolene 3046
2115
586-62-9
Liquid
C10H16
136.24
Insoluble
Insoluble
183-185
NMR
95 %
1.474-1.484
0.872-0.882
01.006
1328
alpha-Phellandrene 2856
2117
99-83-2
Liquid
C10H16
136.24
Insoluble
Soluble
175
IR
95 %
1.471-1.477
0.845-0.855 Racemate.
Flavouring Group Evaluation 78 Revision 2
EFSA Journal 2015;13(4):4067 16
Table 3: Specifications Summary for the JECFA Evaluated Substances in the Present Group (JECFA, 2005a)
FL-no
JECFA
-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index
(d)
Spec.gravity
(e)
EFSA comments
01.007
1324
beta-Caryophyllene 2252
2118
87-44-5
Liquid
C15H24
204.36
Insoluble
Soluble
256
IR
80 %
1.498-1.504
0.899-0.908 80-92 % β-
caryophyllene; 10-15 %
α-humulene; 5-6 % 
valencene and other
C15H24 hydrocarbons as
isolated from natural
sources.
01.008
1327
Myrcene 2762
2197
123-35-3
Liquid
C10H16
136.24
Insoluble
Soluble
166-167
NMR
90 %
1.466-1.471
0.789-1.793 At least 90 % myrcene;
secondary components
1-5 % limonene, 1-2 %
ocimene and trace
amounts of pinene and
dimers of myrcene.
01.009
1323
Camphene 2229
2227
79-92-5
Solid
C10H16
136.24
Insoluble
Soluble
n.a.
52
NMR
80 %
n.a.
n.a. Racemate. At least 80
% camphene; secondary
components 10-12 %
Fenchene; 4-5 %
limonene and trace
amounts of pinene,
myrcene and other
terpene hydrocarbons.
01.010
1333
1-Isopropenyl-4-
methylbenzene
3144
2260
1195-32-0
Liquid
C10H12
132.20
Insoluble
Soluble
186-189
NMR
97 %
1.532-1.535
0.846-0.854
01.011
1334
4-Methyl-1,1’-
biphenyl
3186
2292
644-08-6
Solid
C13H12
168.24
Insoluble
Soluble
n.a.
49-50
NMR
98 %
n.a.
n.a.
No longer supported by
Industry (DG SANCO,
2012).
01.013
1332
Biphenyl 3129
10978
Solid
C12H10
Insoluble
Soluble
254
69
n.a.
n.a.
No longer supported by
Industry (DG SANCO,
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Table 3: Specifications Summary for the JECFA Evaluated Substances in the Present Group (JECFA, 2005a)
FL-no
JECFA
-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index
(d)
Spec.gravity
(e)
EFSA comments
92-52-4 154.21 NMR
99 %
2012).
01.014
1335
1-Methylnaphthalene 3193
11009
90-12-0
Liquid
C11H10
142.20
Insoluble
Soluble
241-245
NMR
97 %
1.612-1.618
1.020-1.025
No longer supported by
industry (DG SANTE,
2015).
01.016
1336
1,4(8),12-
Bisabolatriene
3331
10979
495-62-5
Liquid
C15H24
204.36
Insoluble
Insoluble
262
NMR
97 %
1.493-1.497
0.850-0.858
01.017
1337
Valencene 3443
11030
4630-07-3
Liquid
C15H24
204.36
Insoluble
Insoluble
123 (14 hPa)
NMR
94 %
1.498-1.508
0.914-0.919 CASrn refers to (+)-
Valencene. At least 94
% valencene; secondary
components 1-2 %
bisabolene and 1-2 %
farnesene.
01.018
1338
beta-Ocimene
(E)- isomer shown
3539
11015
13877-91-3
Liquid
C10H16
136.24
Insoluble
Soluble
177
NMR
80 %
1.478-1.491
0.801-0.805 80 %; mixture of (E)-
and (Z)-isomers. 50-70
% ( E)-isomer (EFFA,
2014). Secondary
component 15-17 % cis-
ß-Ocimene. CASrn in
Register does not
specify stereoisomeric
composition.
01.019
1339
alpha-Terpinene 3558
11023
99-86-5
Liquid
C10H16
136.24
Insoluble
Soluble
173
NMR
89 %
1.475-1.480
0.833-0.838 At least 89 % α-
terpinene; secondary
components 3-5 % 1,8-
and 2-3 % 1,4-cineole
(EFFA, 2014).
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Table 3: Specifications Summary for the JECFA Evaluated Substances in the Present Group (JECFA, 2005a)
FL-no
JECFA
-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index
(d)
Spec.gravity
(e)
EFSA comments
01.020
1340
gamma-Terpinene 3559
11025
99-85-4
Liquid
C10H16
136.24
Insoluble
Soluble
182
NMR
95 %
1.472-1.478
0.841-0.845 According to JECFA:
Min. assay value is "95
%" and "may include
traces of limonene,
alpha and beta- pinene
and other common
C10H16 terpenes".
01.024
1345
beta-Bourbonene H
H H
11931
5208-59-3
Liquid
C15H24
204.36
Insoluble
Soluble
121 (14 hPa)
NMR
96 %
1.500-1.507
0.899-0.908 Stereoisomeric
composition specified
by CASrn and name in
Register. According to
JECFA: Min. assay
value is ”96 %” and
”may include traces of
other C15H24
compounds (cadinene,
guaiene, farnesene)”. 4
% consist of C15H24
compounds.
01.026
1347
1(5),7(11)-
Guaiadiene
S
S
88-84-6
Liquid
C15H24
204.36
Insoluble
Soluble
118 (3 hPa)
NMR
96 %
1.503-1.509
0.912-0.918 Stereoisomeric
composition specified
by CASrn and name in
Register. According to
the JECFA: Min. assay
value is ”96 %” and
”may include traces of
other C15H24
compounds (cadinene,
farnesene, valencene)”.
4 % consist of C15H24
compounds.
Flavouring Group Evaluation 78 Revision 2
EFSA Journal 2015;13(4):4067 19
Table 3: Specifications Summary for the JECFA Evaluated Substances in the Present Group (JECFA, 2005a)
FL-no
JECFA
-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index
(d)
Spec.gravity
(e)
EFSA comments
01.029
1342
delta-3-Carene 3821
10983
13466-78-9
Liquid
C10H16
136.24
Insoluble
Slightly
soluble
169-174
NMR
92 %
1.468-1.478
0.860-0.868 Racemate. At least 92
%; secondary
components 2-3 % β-
pinene; 1-2 %
limonene; 1-2 %
myrcene; 0-1 % p-
cymene.
01.040
1343
alpha-Farnesene 3839
10998
502-61-4
Liquid
C15H24
204.36
Insoluble
Slightly
soluble
53-57 (1 hPa)
NMR
67 %
1.490-1.500
0.834-0.845 38-50 % α-isomer, 29-
40 % ß-isomer and
secondary components:
10-15 % bisabolene and
up to 2-3 % each of
valencene, bourbonene,
cadinene and guaiene
(EFFA, 2014).
01.045
1326
d-Limonene 2633
491
5989-27-5
Liquid
C10H16
136.24
Insoluble
Soluble
175-177
IR
96 %
1.471-1.477
0.838-0.843 According to the
JECFA: Min. assay
value is ”96 % (sum of
d/l isomers)” and
”Compounds present
above 0.5 %: linalool,
myrcene”. In commerce
d-Limonene is defined
as 90-93 % d-isomer
and 2-6 % l-isomer
(EFFA, 2014).
01.061
1341
Undeca-1,3,5-triene 3795
16356-11-9
Liquid
C11H18
150.26
Slightly
soluble
Soluble
80-81 (16 hPa)
NMR
94 %
1.510-1.518
0.788-0.796 Assay value: 94 % (54-
56 % 3E,5Z-isomer, 35-
37 % 3Z,5E-isomer and
3-5 % 3E,5E-isomer)
and 1-3 % secondary
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Table 3: Specifications Summary for the JECFA Evaluated Substances in the Present Group (JECFA, 2005a)
FL-no
JECFA
-no
EU Register name Structural formula FEMA no
CoE no
CAS no
Phys.form
Mol.formula
Mol.weight
Solubility (a)
Solubility in
ethanol (b)
Boiling point, °C (c)
Melting point, °C
ID test
Assay minimum
Refrac. Index
(d)
Spec.gravity
(e)
EFSA comments
component: 2,4,6-
undecatriene
(2Z,4Z,6E) (EFFA,
2014). CASrn in
Register does not
specify stereoisomers.
01.077
1344
1-Methyl-1,3-
cyclohexadiene
1489-56-1
Liquid
C7H10
94.16
Insoluble
Soluble
118-120
NMR
95 %
1.446-1.452
0.846-0.853
(a): Solubility in water, if not otherwise stated.
(b): Solubility in 95 % ethanol, if not otherwise stated.
(c): At 1013.25 hPa, if not otherwise stated.
(d): At 20°C, if not otherwise stated.
(e): At 25°C, if not otherwise stated.
n.a. not applicable
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4. Genotoxicity Data
4.1. Genotoxicity Studies – Text Taken7F13 from the JECFA (JECFA, 2006a)
Aliphatic and alicyclic hydrocarbons
In vitro
No evidence of mutagenicity was observed in Ames assays when camphene ([FL-no: 01.009]; up to
84,200 µg/plate), beta-caryophyllene ([FL-no: 01.007]; up to 150,000 µg/plate), d-limonene ([FL-no:
01.045]; up to 150,000 µg/plate), myrcene ([FL-no: 01.008]; up to 10,000 µg/plate), alpha-pinene
([FL-no: 01.004] (pin-2(3)-ene); up to 25,000 µg/plate), beta-pinene ([FL-no: 01.003] (pin-2(10)-ene);
up to 5000 µg/plate), or p-mentha-1,4-diene ([FL-no: 01.020] (gamma-terpinene); up to 50,000
µg/plate) were incubated with Salmonella typhimurium strains TA97, TA98, TA100, TA1535,
TA1537, TA1538, and/or UTH8413, UTH8414, or TA102 with and without metabolic activation
(Rockwell and Raw, 1979; Florin et al., 1980; DeGraff, 1983; Haworth et al., 1983; Jagannath, 1984a;
Jagannath, 1984b; Connor et al., 1985; Heck et al., 1989; NTP, 1990; Müller et al., 1993; NTP, 2004b;
NTP, 2004c). Without metabolic activation, delta-3-carene [FL-no: 01.029] at doses of between 2157
and 4314 µg/plate gave positive results in the Ames assay in S. typhimurium strains TA100 and
TA102, but gave negative results in both strains with metabolic activation (Kurttio et al., 1990). delta-
3-Carene at doses of up to 4314 µg/plate also gave negative results in S. typhimurium strain TA98
with and without metabolic activation (Kurttio et al., 1990). In one Ames assay with S. typhimurium
strains TA98, TA100, TA1535 and TA1537, the beta-isomer of cadinene (JECFA-no: 1346) gave
negative results at doses of up to 10 000 and 3333 µg/plate, respectively, with and without metabolic
activation (Haworth et al., 1983; NTP, 2004e). In another Ames assay, cadinene (isomer not specified)
gave equivocal/weak positive results at doses of up to 10 000 µg/plate in S. typhimurium strains TA97
and TA100 with metabolic activation, but gave negative results at doses of up to 100 µg/plate in both
strains without metabolic activation, as well as in strains TA98, TA1535 and TA1537 with and
without metabolic activation (NTP, 2004d).
Camphene ([FL-no: 01.009]; 1.4–136.2 µg/ml), beta-caryophyllene ([FL-no: 01.007]; 2.0– 204.4
µg/ml), alpha-phellandrene ([FL-no: 01.006]; 4.5–136.2 µg/ml), and beta-pinene (FL-no: 01.003; 4.5–
136.2 µg/ml) did not induce sister chromatid exchanges (SCE) in Chinese hamster ovary cells without
metabolic activation (Sasaki et al., 1989).
Beta-caryophyllene ([FL-no: 01.007]; up to 10 000 µg/ml), alpha-pinene ([FL-no: 01.004]; up to 10
000 µg/ml), and p-mentha-1,4-diene ([FL-no: 01.020]; up to 30 µg/ml) did not induce unscheduled
DNA synthesis in rat hepatocytes (Heck et al., 1989).
d-limonene [FL-no: 01.045] did not induce genetic effects when tested in Saccharomyces cerevisiae
strain MP1, without metabolic activation, at concentrations of up to 230 mmol/l (Fahrig, 1984). In
Chinese hamster ovary cells, d-limonene did not induce chromosomal aberrations at concentrations of
10 - 500 µg/ml, or SCE at concentrations of 1.4 - 162 µg/ml, with and without metabolic activation
(Sasaki et al., 1989; Anderson et al., 1990; NTP, 1990). In an assay for forward mutation in mouse
lymphoma cells, d-limonene produced negative results in L5178Y cells with and without metabolic
activation, at a concentration of up to 100 µg/ml (Heck et al., 1989; Myhr et al., 1990; NTP, 1990).
When incubated with Syrian hamster embryo cells, limonene (isomer not specified) did not induce cell
transformation in one assay at a concentration of up to 100 µg/ml (Pienta, 1980), while in another
assay concentrations up to 408.7 µg/ml increased the transformation frequency, albeit not in a
statistically significant manner (Rivedal et al., 2000). The latter study also tested the effects of
limonene (isomer not specified) on gap junction intercellular communication in Syrian hamster
embryo cells. Limonene at concentrations of 1.4 - 136.2 µg/ml did not show effects (Rivedal et al.,
2000).
13 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present
FGE has been removed.
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With and without metabolic activation, myrcene [FL-no: 01.008] did not induce gene mutations at the
hypoxanthine guanine phosphoribosyl transferase (Hprt) locus in Chinese hamster V79 cells, at
concentrations of up to 1000 µg/ml (Kauderer et al., 1991), nor did it induce SCE in these cells at
concentrations up to 500 µg/ml (Röscheisen et al., 1991). Myrcene also did not induce SCE or
chromosomal aberrations in human lymphocytes, with and without metabolic activation, at
concentrations of up to 1000 µg/ml (Kauderer et al., 1991), nor did it induce SCE in hepatic tumour
cells, at concentrations of up to 500 µg/ml, although a slight, reproducible but not dose-dependent
increase was noted (Röscheisen et al., 1991).
The beta-isomer of cadinene (No. 1346, not in Register) gave negative results in an assay for forward
mutation in mouse lymphoma cells , at concentrations of up to 46.2 µg/ml without metabolic
activation, and at up to 73.9 µg/ml with metabolic activation (NTP, 2004f). In Chinese hamster ovary
cells, this β-isomer did not induce chromosomal aberration with or without metabolic activation at 
concentrations of 24.9 - 40 µg/ml, or SCE with metabolic activation at concentrations of up to
31.1 µg/ml (NTP, 2004g). Without metabolic activation, an equivocal result was obtained for
induction of SCE, at concentrations up to 26.6 µg/ml (NTP, 2004f).
In a study conducted in vivo-in vitro, designed to investigate the mutagenicity of urinary metabolites
of a number of food additives, Sprague-Dawley rats were given a single dose of 0.5 ml of camphene
(FL-no: 01.009; approximately 1684 mg/kg bw) and α-pinene (FL-no: 01.004; approximately 1718 
µg/kg bw) via gavage and the urine was collected for 24 h. Three types of urine sample were tested in
the Ames assay with S. typhimurium strains TA98 and TA100 with metabolic activation: a direct urine
sample, a urine-ether extract, and the aqueous fraction of the urine-ether extract. The urine samples of
rats treated with α-pinene did not show any evidence of mutagenicity, either in the presence or absence 
of beta-glucuronidase. Of the urine samples of camphene-treated rats only the urine-ether extract
showed a weak mutagenic response, and only in TA100, not in TA98 (Rockwell and Raw, 1979).
In vivo
In a mammalian spot test, no evidence of mutagenicity was observed in mouse C57BLxT embryos in
utero after intraperitoneal injection of the dam with d-limonene [FL-no: 01.045] at a dose of
215 mg/kg bw per day on days 9 and 10 of gestation (Fahrig, 1984).
In an assay for cytogenetic changes in bone marrow, groups of Wistar rats (two or four of each sex per
group) were given myrcene [FL-no: 01.008] at a dose of 100, 500, or 1000 mg/kg bw via gavage. A
negative control group (two rats of each sex) received only the vehicle (corn oil) via gavage, while a
positive control group (two rats of each sex) received cyclophosphamide at a dose of 30 mg/kg bw via
intraperitoneal injection. A mitotic inhibitor (colchicine, administered at a dose of 5 mg/kg bw via
intraperioneal injection) was administered 1 h before sacrifice at 24 or 48 h after treatment, at which
time the bone-marrow cells were harvested. Compared with the negative control group, treatment with
myrcene did not result in an increase of metaphase cells with chromosomal aberrations upon
examination at 24 or 48 h. In contrast, in the positive control group chromosomal aberrations were
found in 19 % of the bone-marrow metaphase cells examined. Although not clastogenic, myrcene
caused a dose-dependent increase in the mitotic index in bone-marrow cells, indicating that it was
present at a sufficient dose in the target tissue (Zamith et al., 1993).
An assay for micronucleus formation in mouse peripheral blood erythrocytes was performed, with
samples of peripheral blood obtained within 24 h of the final exposure in a 13-week study of toxicity
in which male and female B6C3F1 mice were given myrcene [FL-no: 01.008] at a dose of up to
2000 mg/kg bw per day via gavage. Scoring of 1000 normochromatic erythrocytes (NCEs) for
micronuclei revealed no increase in micronucleated NCEs at any dose (NTP, 2004h).
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Conclusion on genotoxicity on aliphatic/alicyclic hydrocarbons
Seven substances in this group of flavouring agents have been tested in the Ames assay and found not
to be mutagenic in bacteria in vitro. One flavouring agent, δ-3-carene, produced a positive result in 
this assay, only without metabolic activation, in S. typhimurium strains TA100 and TA102 but not
TA98. Another flavouring agent, cadinene (isomer not specified), gave weakly positive results in the
Ames assay, only with metabolic activation, in S. typhimurium strains TA97 and TA100 but not TA98,
TA1535, and TA1537.
In mammalian cell systems, predominantly negative results were obtained for representative members
of this group with respect to induction of SCE, chromosomal aberrations, unscheduled DNA synthesis,
and gene mutations. In assays for cell transformation in Syrian hamster embryo cells, limonene
(isomer not specified) gave negative results in one assay, but weak positive results in another, the
increase in transformation frequency being not statistically significant.
Myrcene and d-limonene showed no signs of genetic toxicity in cytogenetic assays for micronucleus
formation in bone marrow and peripheral erythrocytes (myrcene) and a mammalian spot test (d-
limonene) performed in vivo.
On the basis of the results of available studies of genotoxicity, the Committee concluded that the
flavouring agents in this group of aliphatic and alicyclic hydrocarbons are not genotoxic.
Aromatic hydrocarbons
In vitro
No evidence of mutagenicity was observed in standard or modified Ames assays when p-cymene
([FL-no: 01.002]; up to 85,300 µg/plate), was incubated with Salmonella typhimurium strains TA98,
TA100, with metabolic activation (Rockwell and Raw, 1979).
In a study designed to investigate the mutagenicity in vivo-in vitro of urinary metabolites of a number
of food additives, Sprague-Dawley rats were given 0.5 ml of p-cymene ([FL-no: 01.002];
approximately 1706 mg/kg bw) by gavage and urine was collected for 24 hours. Three types of urine
samples were tested in the Ames assay with S. typhimurium strains TA98 and TA100 with metabolic
activation: a direct urine sample, a urine-ether extract, and the aqueous fraction of the urine-ether
extract. The urine samples of rats treated with p-cymene did not show any evidence of mutagenicity,
either in the presence or absence of β-glucuronidase (Rockwell and Raw, 1979). 
Conclusion on genotoxicity on aromatic hydrocarbons
One substance in this group of flavouring agents has been tested in the Ames assay and found not to
be mutagenic in vitro in bacteria. On the basis of the results of available studies of genotoxicity, the
Committee concluded that the flavouring agents in this group of aromatic hydrocarbons are not
genotoxic.
For a summary of in vitro/in vivo genotoxicity data considered by the JECFA, see Tables 5 and 6.
4.2. Genotoxicity Studies – Text Taken8F14 from EFSA FGE.25Rev3 (EFSA CEF Panel, in
press)
Data from in vitro tests are available for two candidate substances [subgroup I: FL-no: 01.038 and FL-
no: 01.057] and 10 supporting flavouring substances [one from subgroup II, four from subgroup III,
and five from subgroup V (for pin-2(3)-ene [FL-no: 01.004] also data for separate stereoisomers were
14 The text is taken verbatim from the indicated reference source, but text related to substances not included in the present
FGE has been removed.
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available (+ and -)- α-pinene), and one structurally related substance, (2-methylbuta-1,3-diene) not 
used as flavouring substance from subgroup II. Data for three supporting substances [FL-no: 01.008
(subgroup II), FL-no: 01.019 (subgroup III), FL-no: 01.004 (subgroup V), and data for the structurally
related substance from subgroup II are considered valid.
Data from in vivo tests are available for two supporting substances (one from subgroup II and one
from subgroup III) and for one substance structurally related to subgroup II (2-methylbuta-1,3-diene).
Candidate substances
Subgroup I
The two candidate substances [FL-no: 01.038 and 01.057] tested in vitro for bacterial gene mutations
gave negative results in bacterial reverse gene mutation tests and for mammalian cell gene mutations.
Subgroup II
For the three candidate substances in subgroup II [FL-no: 01.035, 01.064 and 01.070] there are no
genotoxicity data available, but it was noted that in contrast to the structurally related substance 2-
methyl-1,3-butadiene, these substances do not contain conjugated terminal double bonds, except [FL-
no: 01.064].
The available in vivo studies on the structurally related substance 2-methylbuta-1,3-diene (isoprene)
reported a negative result in a valid chromosomal aberration assay in the bone marrow of mice after 12
days of inhalatory exposure to isoprene. However, isoprene induced sister chromatid exchanges (SCE)
in the bone marrow and micronuclei in peripheral blood cells of mice after 12 days of inhalatory
exposure in two valid studies carried out within NTP. Induction of micronuclei in peripheral blood
cells of mice has also been reported after inhalatory exposure for 13 weeks. In contrast, inhalatory
exposure of isoprene to male and female rats for four weeks did not result in an increase in the
frequency of micronuclei in the lung fibroblasts. The validity of the latter two studies cannot be
evaluated due to limited details available. Isoprene has been reported to bind covalently to
haemoglobin in vivo (IARC, 1999).
The genotoxic and carcinogenic potential of isoprene has been evaluated by IARC (1999a). It was
concluded that there is sufficient evidence of carcinogenicity in experimental mammalians and that
isoprene is ‘possibly carcinogenic to humans’ (Group 2B) (IARC, 1999). Isoprene has been classified
in the EU as a ‘Muta. Cat. 3; R68’ and ‘Carc. Cat. 2; R45’ (EFSA, 2004b).
The available data on in vivo genotoxicity of isoprene indicate a genotoxic potential of the substance.
In the light of the evidence of carcinogenic activity of isoprene in rats and mice (NTP, 1999) and the
genotoxic effects of isoprene in mice and the fact that the structurally related substance 1,3-butadiene
is classified as a genotoxic carcinogen, the Panel concluded that there is reason for concern with
respect to genotoxicity and carcinogenicity of isoprene. This substance has been deleted from the
Register.
For the supporting substances myrcene, several in vitro genotoxicity tests and three in vivo
genotoxicity studies were available. All the in vitro genotoxicity tests on myrcene were negative. Two
micronucleus tests on peripheral blood cells and one chromosomal aberration assay with myrcene
gave negative results.
Conclusion on Genotoxicity for subgroup II
The supporting substance myrcene [FL-no: 01.008], which by the Panel is considered a more adequate
supporting substance for the substances in subgroup II, has like isoprene, two conjugated terminal
double bonds but has a longer chain length, with 10 carbon atoms, like [FL-no: 01.064]. The
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genotoxicity data available on myrcene do not give rise to concern with respect to genotoxicity.
Therefore, the Panel has not concern for genotoxicity for the three substances in subgroup II.
Subgroup III
For the five candidate substances in subgroup III no genotoxicity studies were available. For the four
supporting substances, d-limonene [FL-no: 01.045], gamma-terpinene [FL-no: 01.020], α-terpinene 
[FL-no: 01.019] and α-phellandrene [FL-no: 01.006], several in vitro studies on genotoxicity were
available and they were all negative. Also two in vivo Comet assay with d-limonene and a study with
d-limonene in BigBlueTM rats were found negative. Therefore, the Panel has no concern for
genotoxicity for the substances in subgroup III.
Subgroup V
For the candidate substance in subgroup V there are no genotoxicity data available. For the supporting
substances, only negative results were reported in the available studies except for delta-3-carene (see
Table 7). Delta-3-carene was studied individually as a component in wood fumes and wood fume
condensates. A bacterial reverse gene mutation study (insufficiently reported) showed that delta-3-
carene induced gene mutations in TA100 and TA102 strains in the absence of metabolic activation at
high concentrations only, while it was negative in the presence of metabolic activation (Kurttio et al.,
1990).
Information on the supporting substance β-caryophyllene [FL-no: 01.007] has been provided by EFFA 
(EFFA, 2012). The new data submitted cover a bacterial reverse mutation assay and an in vivo mouse
erythrocyte micronucleus test.
In vitro
No evidence of genotoxic potential was observed when S. typhimurium strains TA98 and TA100 and
E. coli WP2uvrA were incubated with five test concentrations between 2300 and 9000 μg/plate in the 
presence or absence of rat liver (S9) bioactivation system using the plate incorporation method (Di
Sotto et al., 2008). The positive and negative controls provided the appropriate response in the tester
strains. However, the study design and reporting exhibits major deviations from OECD guideline 471
and is considered of insufficient quality.
In vivo
In an in vivo micronucleus induction assay, groups of mice (National Institute of Hygiene, Mexico)
(5/sex/dose) were administered a single dose of 0, 20, 200 and 2000 mg/kg bw of β-caryophyllene by 
corn oil gavage. Blood was drawn and smears for analysis were prepared at 24, 48, 72 and 96 hours
post dose. No significant increase in the induction of micronucleated polychromatic erythrocytes
(MNPE) was observed for the treatments groups while all positive controls provided the appropriate
response (Molina-Jasso et al., 2009). In a follow up study groups of the same strain of mice
(5/sex/dose) were administered daily doses of 0, 20, 200 and 2000 mg/kg bw for three consecutive
days by corn oil gavage with blood sampled and smears for analysis prepared at 24, 48, 72 and 96
hours post administration. There was no significant increase in MNPE however there was a slight
increase in MNPE at the highest dose tested from 48 - 96 hours post dose. The authors did not
consider this an indication of genotoxic potential due to the high dose administered over three
consecutive days (Molina-Jasso et al., 2009). The Panel noted that the limit dose (2000 mg/kg) was
applied in both treatment regimens without signs of toxicity (altered PCE/NCE ratio). The study is
compliant with OCED guideline 474, except the reporting of individual data and historical controls;
therefore, this study is considered of limited validity.
Altogether, the Panel has no concern for genotoxicity for the substances in subgroup V.
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Data on genotoxicity are summarised in Table 7 and 8.
Data on the genotoxicity of the flavouring substances in this group are limited and the genotoxicity
could not be assessed adequately for these substances. However, the Panel concluded that the available
data do not preclude evaluating the 14 candidate substances using the Procedure.
4.3. New Mutagenicity/Genotoxicity Studies on β-Caryophyllene [FL-no: 01.007] 
Information on the representative substance β-caryophyllene [FL-no: 01.007] has been provided by 
EFFA (EFFA, 2012). The new data submitted cover a bacterial reverse mutation assay and an in vivo
mouse erythrocyte micronucleus test.
In vitro
No evidence of genotoxic potential was observed when S. typhimurium strains TA98 and TA100 and
E. coli WP2uvrA were incubated with 5 test concentrations between 2300 and 9000 μg/plate in the 
presence or absence of rat liver (S9) bioactivation system using the plate incorporation method (Di
Sotto et al., 2008). The positive and negative controls provided the appropriate response in the tester
strains. However, the study design and reporting exhibits major deviations from OECD guideline 471
(see Table 9).
In vivo
In an in vivo micronucleus induction assay, groups of mice (5/sex/dose; mouse strain from National
Institute of Hygiene (NIH), Mexico) were administered by gavage as a single dose of 0, 20, 200 and
2000 mg/kg bw of β-caryophyllene solved in corn oil. Blood was drawn and smears for analysis were 
prepared at 24, 48, 72 and 96 hours post dose. No significant increase in the induction of
micronucleated polychromatic erythrocytes (MNPE) was observed for the treatment groups while all
positive controls provided the appropriate response (Molina-Jasso et al., 2009). In a follow up study
groups of NIH mice (5/sex/dose) were administered daily doses of 0, 20, 200 and 2000 mg/kg bw for
three consecutive days by gavage with blood sampled and smears for analysis prepared at 24, 48, 72
and 96 hours post administration. The Panel noted that the limit dose (2000 mg/kg) was applied in
both treatment regimens without signs of toxicity (altered reticulocyte/NCE ratio). A slight, non-
significant increase in the MNPE frequency was observed in the highest dose group at 48, 72 and 96
hours, respectively. However, at none of these time points the effects were clearly dose-related since
the low and medium doses resulted in lower MNPE frequencies than that observed in control animals.
Overall, the Panel concluded that β-caryophyllene did not cause a significant increase in MNPE. 
However, the study exhibits deviations from OECD guideline 474 and therefore, is considered to be of
limited validity (see Table 9).
Although the newly submitted data are of limited validity they do not preclude the substances to be
evaluated using the Procedure.
For a summary of in vitro / in vivo genotoxicity data on β-caryphyllene, see Table 9. 
4.4. EFSA Considerations
The Panel agrees with the JECFA conclusions on genotoxicity.
5. Data Submitted Since Publication of FGE.78Rev1
A 90-day study requested in the previous version of this FGE was submitted for ß-caryophyllene [FL-
no: 01.007] (Bauter, 2013a) along with a 14-day study (Bauter, 2011).
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5.1. 14-Day Study on β-Caryophyllene [FL-no: 01.007] 
In a 14 day range finding dietary study (Bauter, 2011), groups (3/sex/dietary intake level) of male and
female Hsd:SD® rats were fed a diet designed to provide 0 (dietary control), 6000, 18 000 and 48 000
mg/kg feed of β-caryophyllene daily. These estimated dietary levels correspond to the measured intake 
of 0, 516, 1547 and 3569 mg/kg bw per day for males and 0, 528, 1582 and 4438 mg/kg bw per day
for females, respectively. Clinical observations were recorded daily and body weights and food
consumption observations were made on days 0, 7 and 14. There were no mortalities. Hyperactivity
observed in 1/3 (33 %) of males and females in group 4 (48 000 mg/kg feed) in the latter part of the
study may be possibly attributed to test substance administration. Dose-dependent decreases in male
food consumption and food efficiency with significant corresponding decreases in group 4 male body
weight and body weight gain were considered a result of test substance administration, but were not
correlated with any other clinical signs. Females did not exhibit significant differences from female
control. Findings at terminal sacrifice included all (100 %) males and females of group 4 with
distention (cecum) and slight redness of the stomach, small intestines, and cecum. Based upon the
limited toxicological endpoints evaluated, the study authors selected doses for the 90-day study.
5.2. 90-Day Study on β-Caryophyllene [FL-no: 01.007] 
In an OECD 408 compliant 90-day study, 4 groups of rats (10/sex/dietary intake level) of male and
female CRL Sprague-Dawley CD®IGS rats were fed a diet designed to provide 0 (dietary control),
3500, 7000 and 21 000 mg/kg feed and 3500, 14 000 and 56 000 mg/kg feed of β-caryophyllene for 
males and females, respectively, daily (Bauter, 2013a). These dietary levels corresponded to measured
daily intakes of 0, 222, 456 and 1367 mg/kg bw for males and 0, 263, 1033 and 4278 mg/kg bw for
females, respectively (Bauter, 2013a). The purity of the β-caryophyllene preparation was between 99 
% (start of study) and 96 % (end of study). Clinical observations of toxicity were performed on day 0
and weekly until sacrifice. Animals were weighed on day 0 at the start of the study and weekly
thereafter. Food consumption and efficiency were measured and calculated weekly. Blood chemistry
and haematology were performed on blood drawn via sublingual bleed during week 12 after overnight
fast. Urine was collected during the 15 hours prior to the blood draw. Prior to initiation of the study
and on day 91 the eyes of all rats were examined by focal illumination and indirect ophthalmoscopy.
At termination of the study all survivors were sacrificed and subject to full necropsy.
There were no mortalities, clinical signs of toxicity or ophthalmological changes associated with the
presence of β-caryophyllene in the diet. There were statistically significant and concentration-related 
reductions in body weight gain, food consumption and food efficiency in males and females at the 21
000 mg/kg feed and 56 000 mg/kg feed concentration groups, respectively (body weight of high dose
groups: males 77.3 %, females 82.6 % as compared to controls).
Although for some parameters statistically significant differences were found when compared to
concurrent controls, haematology, clinical chemistry, coagulation and urine analysis parameters for the
middle and high concentrations for both males in general were within the range of historical controls.
Most of these changes were small, and observed in the highest dose group. Thus, in the female test
groups, a statistically significant increase for platelet count was reported at the highest dietary level;
such an increase was not observed in the male test groups. A dose dependent increase in white blood
cells in males reached statistical significance at the middle and high dose; several other blood cells
showed significant changes at the highest dose as well in males; the effects in females were less
pronounced. There were no histopathology findings correlating to these variations.
In females a dose-dependent decrease in serum glucose concentrations and an increase in triglyceride
levels reached statistically significance only at the highest dose level. In conjunction with changes
reported in the liver these changes were attributed to metabolic changes as a result of high
concentrations of β-caryophyllene in the diet. Pathological findings include increases in absolute and 
relative liver weights; these were found statistically significant in the mid- and high-dose groups of
both sexes. Histopathological liver changes at the mid and high intake levels for both sexes were
characterized by centrilobular to midzonal distributed hepatocellular hypertrophy. Based on
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hepatocyte hypertrophy in both sexes, the increases in absolute and/or relative liver weights at the
mid- and highest dietary levels, and the absence of any other significant abnormality upon
histopathological examination, the study authors conclude that the hepatocyte hypertrophy is the result
of hepatic enzyme induction; this has, however, not been confirmed by measurements of relevant
enzymes.
Necropsy revealed enlarged kidneys in one male at the highest test concentration and significant
increases in relative kidney weight of male high-dose as well as of female mid- and high-dose groups.
Microscopic examination revealed mononuclear infiltration in only one of ten females of the highest
dose group. No other microscopically visible alterations were reported in the kidneys of female rats.
The increase in kidney weights in female remains unexplained. Microscopical examination of the
kidney of males revealed an increased incidence of nephropathy characterised by regeneration of
proximal cortical tubules with thickened membranes, mononuclear cell infiltration and tubular casts at
all dose levels. The severity of the nephropathy exhibited a dose-dependent shift from low to high
grades. Kidney cells of affected males also were reported to have necrotic nuclei and an increase in
eosinophilic cytoplasm. Likewise, in the kidneys of all treated males eosinophilic cytoplasmic droplets
were present, with a dose-dependent shift to higher grades. In a supplementary study the kidney slides
of exclusively male rats were stained also with Mallory Heidenhain stain (Zook and Garlick, 2013),
which results in enhanced staining of the cytoplasmic droplets (De Rijk et al., 2003; Frazier et al.,
2012); this confirmed the observations of the eosine staining. An increased hyaline droplet
accumulation in male rats exclusively is characteristic of α2u-globulin nephropathy (Hard et al., 1993),
which is considered a male rat specific effect with little relevance for humans. Although no specific
immunohistochemical staining of α2u –globulin has been done to confirm the presence of this protein,
the Panel considers the evidence sufficient to conclude that this kidney toxicity in male rats
exclusively is not relevant for humans.
Microscopic examination of the mesenteric lymph nodes revealed the presence of erythrocytes in the
sinuses at the mid- and high-intake levels for both sexes. Additionally, reduced spleen weights for
males at the highest dietary level were considered related to general reductions in lymphoid system
weights.
The Panel concluded that under the conditions of the present 90-day dietary toxicity study and based
on the toxicological findings in haematology in males, the liver, the mesenteric lymph node pathology
in both sexes and non-explained effects in female kidneys only the lowest dose provides a no-adverse-
effect level (NOAEL) for β-caryophyllene, which is the lowest in male rats: 222 mg/kg bw per day.  
5.3. 90-Day Study on Myrcene [FL-no: 01.008]
90-Day Study by the NTP (2010); Administration by Gavage.
Groups of 10 male and 10 female F344/N rats were administered 0, 250, 500, 1000, 2000 or 4000 mg
myrcene/kg body weight in corn oil by gavage, five days per week for 14 weeks. Additional groups of
10 male and 10 female special study rats were administered the same doses for 23 days (NTP, 2010).
The results of this study have been summarised in more detail in FGE 25Rev3.
All rats in the 4000 mg/kg bw groups died. One to three rats in the 1000 and 2000 mg/kg groups and
one 500 mg/kg bw male died by week 10 of the study. Mean body weights were significantly
decreased in male rats in the 500, 1000, and 2000 mg/kg bw groups. Right kidney and liver weights of
dosed males and females were generally significantly greater than those of the vehicle controls. In
special study rats evaluated on day 23, the incidences and severities of chronic progressive
nephropathy (CPN) and renal tubule degeneration were increased in 2000 mg/kg bw males. At the end
of the 3-month study, the incidences of renal tubule necrosis were significantly increased in all dosed
groups of males and females. Of the core control males 7 out of 10 showed nephropathy at the end of
the study; in the low dose group this was 10/10. For females 1/10 controls showed nephropathy while
for the low dose group this was 2/10. In all cases the nephropathy was judged to be minimal. At 3
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months, the incidences of olfactory epithelium degeneration in 2000 mg/kg bw males and females
were significantly increased, and the severities were increased. The incidences of chronic
inflammation in 1000 and 2000 mg/kg bw males and females were significantly increased. All 2000
mg/kg bw males and females had splenic atrophy. In the mesenteric lymph node, significantly
increased incidences of atrophy occurred in 2000 mg/kg bw males and 1000 and 2000 mg/kg bw
females. Acute inflammation of the forestomach occurred in four 2000 mg/kg bw females. The
incidences of porphyrin pigmentation in the Harderian gland of males administered 500 mg/kg bw or
greater were significantly increased.
The results indicate that at the lowest dose of 250 mg myrcene/kg bw by gavage all females and males
showed renal tubule necrosis. The severity of the lesion was judged to be minimal; it increased with
the dose to mild/moderate. These results were confirmed in a 2 year study in rats by gavage of the
same dose. No NOAEL could be established from this study.
90-Day Study by Bauter (2013b); Administration in the Feed.
In an OECD 408 compliant 90-day study the subchronic toxicity of myrcene (93.3 % pure) was
evaluated in male and female rats, based on continuous exposure to the test substance in the diet
(Bauter, 2013b). Four groups of adult Sprague-Dawley rats (10/sex/group) were maintained on diets
prepared to contain 0, 700, 2100, or 4200 mg/kg feed of myrcene. However, as explained below, the
myrcene content of the diet decreased considerably over 7 days, so that every week a new charge of
the diet was prepared. Therefore, the Panel decided to take the concentration on the last day of the
week for quantification of the exposure, rather than the (logarithmic) mean over the whole week.
Based on the stability data, weekly diet refreshment, and measured dietary intake, an adjusted
calculated mean daily intake of 8.0, 40 , and 44 mg/kg bw per day for males, and 9.6, 48 and 53 mg/kg
bw per day for females for 90 days was calculated.
The neat test substance was measured to be stable under the conditions of storage over the course of
this study. Stability of test substance in the diet was evaluated by analysing dietary levels of myrcene
on days 0, 4, 7, and 10 following preparation, as well as daily, for seven days, in an independent
stability assessment. At the beginning, middle, and end of the study, diet preparation samples were
analysed to verify the concentration of myrcene in the diet over the course of the study.
The myrcene content at the 700 mg/kg feed level was found to decrease from 72 to 18 % from day 0 to
day 7, with an average intake of 45 % of the target concentration over the course of the study.
Similarly, the myrcene content at the 2100 mg/kg feed level decreased from 65 to 30 %, with an
average intake of 44 % of the target concentration over the course of the study. The myrcene content
at the 4200 mg/kg feed level decreased from 69 to 17 % from day 0 to day 7, with an average intake of
43 % of the target concentration over the course of the study.
Prior to study initiation and again on day 88, the eyes of all rats were examined by focal illumination
and indirect ophthalmoscopy. The animals were observed for viability, signs of gross toxicity and
behavioural changes at least once daily during the study and weekly for a battery of detailed clinical
observations. Body weights were recorded twice during acclimation, including prior to test initiation
(day 0) and together with food consumption, weekly thereafter and prior to terminal sacrifice. Blood
and urine samples were collected on day 89 from all surviving study animals for urinalysis,
hematology, and clinical chemistry determinations. Coagulation assessments were performed on day
92 or 93, preceding necropsy. Gross necropsies were performed on all study animals and histological
evaluation of selected organs and tissues from control animals (0 mg/kg feed), animals administered
the highest dietary level, and tissues with gross macroscopic observations.
There were no mortalities, clinical, or ophthalmological changes attributable to myrcene
administration. There were no statistically significant, dietary concentration-dependent changes in
body weight, body weight gain, food consumption, or food efficiency in males and females attributed
to the administration of myrcene during the study.
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There were no clinical pathological findings, changes in macroscopic or microscopic histopathology,
or organ weight changes in the groups administered myrcene. Some incidental changes in clinical
chemistry and hematology parameters were within approximate historical control values, did not
correlate with macroscopic or histopathological findings, were without biologic impact, and were
considered not toxicologically relevant. A few histopathological changes were considered incidental,
spontaneous in nature as observed for the age and strain of rat used in this study, and had no
established relationship to administration of the test substance.
Under the conditions of the study and based on the toxicological endpoints evaluated, the no-adverse-
effect level (NOAEL) for administration of myrcene in the diet was determined to be the highest dose-
group, calculated to provide an estimated daily intake of 44 mg/kg bw per day for males and 53 mg/kg
bw per day for females, respectively.
The Panel took note of the fact that two 90-day studies are available on myrcene: the NTP study and
the Bauter study. While the NTP study showed kidney toxicity in all animals at 250 mg/kg bw per day,
the Bauter study observed no toxicity at all in the kidneys at 44 and 53 mg/kg bw per day in males and
females resp. The Panel decided to accept the NOAEL of the Bauter study (44 mg/kg bw per day)
because:
• the NTP study is a gavage study, which leads to higher exposure levels compared to the Bauter
study in which the compound was added in the feed,
• the Bauter study reflects the dietary administration (consumption with food matrix, over a more
extended period of time) in consumers much better than gavage (NTP) study,
• in the Bauter study no kidney toxicity was observed,
• the NOAEL derived from the Bauter study is six-fold lower than the effect level in the NTP
study.
6. Application of the Procedure
6.1. Application of the Procedure to 22 Aliphatic, Alicyclic and Aromatic Hydrocarbons by
the JECFA (JECFA, 2006a)
Aliphatic and alicyclic hydrocarbons
According to the JECFA all 19 aliphatic and alicyclic substances belong to structural class I using the
decision tree approach presented by Cramer et al. (Cramer et al., 1978).
The JECFA concluded 16 aliphatic and alicyclic hydrocarbons at step A3 in the JECFA Procedure –
i.e. the substances are expected to be metabolised to innocuous products (step 2) and the intakes for all
substances are below the thresholds for their structural class I (step A3). For three substances, d-
limonene, myrcene and α-pinene [FL-no: 01.045, 01.008 and 01.004] the estimated daily intake 
exceeds the threshold for structural class I and these substances were evaluated at step A5.
For myrcene [FL-no: 01.008] a lowest-observed-effect level (LOEL) of 250 mg/kg bw per day was
reported for male mice and male and female rats treated by gavage for 13 weeks (NTP, 2004a), while
the same dose was the no-observed-effect level (NOEL) in female mice. This dose is approximately
1800 times greater than the estimated intake of myrcene from its use as a flavouring agent in Europe
(140 µg/kg bw per day) and 83 000 times greater than the estimated intake of myrcene in the USA (3
µg/kg bw per day). The Committee concluded that myrcene would not pose a safety concern at
estimated current intake.
At its 41st meeting, the Committee established an ADI ‘not specified’ for d-limonene [FL-no: 01.045]
on the basis of short- and long-term studies of toxicity in female rats and male and female mice, and
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studies of developmental toxicity in mice, rats and rabbits. In these studies, d-limonene was tested at
doses ranging from 250 to 2800 mg/kg bw per day. Based on the ADI ‘not specified’, the Committee
concluded that d-limonene would not pose a safety concern at the estimated current intakes (660 µg/kg
bw per day in Europe and 210 µg/kg bw per day in the USA).
No toxicological data on α-pinene [FL-no: 01.004] were available. d-Limonene shares structural
characteristics with α-pinene in that both contain a methyl-substituted cyclohexene ring, which 
contains a second alkyl substituent. In d-limonene, this is an isopropenyl group, while in α-pinene the 
second substituent is a dimethyl-substituted methylene bridge. Based on these chemical structures, it
would be predicted that the toxicity of α-pinene would be unlikely to exceed that of d-limonene. Both
compounds are predicted to be metabolised to innocuous products. Metabolism of both compounds is
by hydroxylation of the cyclohexene ring and oxidation of its methyl substituent. d-Limonene
undergoes epoxidation of the endocyclic and allylic double bonds, leading to dihydroxy products. α-
Pinene is converted to several metabolites, including d-limonene, by rat liver microsomes in vitro. The
Committee concluded that d-limonene shared sufficient chemical and metabolic similarities with α-
pinene to be used as a structural analogue for α-pinene at this step of the Procedure. The estimated 
current per capita intakes of α-pinene in Europe (36 µg/kg bw per day) and in the USA (41 µg/kg bw 
per day) are approximately 5 % and 20 %, respectively, of those of d-limonene, and are almost four
orders of magnitude lower than the lowest doses of d-limonene considered in the establishment of its
ADI ‘not specified’. On the basis of these considerations, the Committee concluded that α-pinene 
would not pose a safety concern at estimated current intakes.
In conclusion the JECFA evaluated the 19 substances as to be of no safety concern at the estimated
levels of intake as flavouring substances based on the MSDI approach.
Aromatic hydrocarbons
According to the JECFA [FL-no: 01.002 and 01.010] belong to structural class I using the decision
tree approach presented by Cramer et al. (Cramer et al., 1978).
The JECFA concluded both aromatic hydrocarbons at step A3 in the JECFA Procedure – i.e. the
substances are expected to be metabolised to innocuous products (step 2) and have intakes below the
thresholds for their structural class I (step A3).
In conclusion, the JECFA evaluated aromatic hydrocarbons with [FL-no: 01.002 and 01.010] as to be
of no safety concern at the estimated levels of intake as flavouring substances based on the MSDI
approach.
The evaluations of the in total 21 aliphatic and alicyclic hydrocarbons and aromatic hydrocarbons are
summarised in Table 11: Summary of Safety Evaluation by the JECFA (JECFA, 2005b).
6.2. Application of the Procedure to Aliphatic Hydrocarbons in FGE.25Rev3 (EFSA CEF
Panel, in press)
For the safety evaluation of the 14 candidate substances from chemical group 31, the Procedure as
outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluations of these 14
substances are summarised in Table 12.
Step 1
All 14 candidate substances evaluated using the Procedure are classified into structural class I [FL-no:
01.001, 01.027, 01.028, 01.033, 01.034, 01.035, 01.038, 01.039, 01.046, 01.054, 01.057, 01.059,
01.064 and 01.070], according to the decision tree approach presented by Cramer et al. (Cramer et al.,
1978).
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Step 2
On the basis of the metabolism information available, five of the six candidate substances of
subgroup I [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057] and five of the six candidate
substances of subgroup III [FL-no: 01.001, 01.027, 01.028, 01.039 and 01.046] (see Table 4) may be
predicted to be metabolised to innocuous products at the estimated levels of intake based on the MSDI
approach, and accordingly the evaluation of these 10 substances proceeds along the A-side of the
Procedure scheme. For the remaining two candidate substances [FL-no: 01.035 and 01.059] there are
not sufficient data available on biotransformation to conclude that they will be metabolised to
innocuous products, and therefore their evaluation will proceed along the B-side of the Procedure
scheme.
Two candidate substances from subgroup II [FL-no: 01.064 and 01.070] contain terminal double
bonds in the absence of other functional groups that may provide alternative routes of detoxication.
Therefore, for these two substances it cannot be concluded that they will be metabolised to innocuous
products, and accordingly they proceed along the B-side of the Procedure scheme.
Step A3
The five candidate substances from subgroup I [FL-no: 01.033, 01.034, 01.038, 01.054 and 01.057]
and the three candidate substances from subgroup III [FL-no: 01.027, 01.028 and 01.039], proceeding
via the A-side, have been assigned to structural class I and have estimated European daily per capita
intakes ranging from 0.012 to 2.7 µg (Table 12). These intakes are below the threshold of concern of
1800 µg/person per day for structural class I. Accordingly, it is concluded that these eight candidate
substances do not pose a safety concern as flavouring substances when used at estimated levels of
intake, based on the MSDI approach. The two candidate substances from subgroup III [FL-no: 01.001
and 01.046] have an estimated European daily per capita intake of 4000 and 2100, respectively, which
are above the threshold of concern of 1800 µg/person per day for structural class I. The evaluation of
these candidate substances will therefore proceed to A4 of the Procedure.
Step A4
The candidate substances [FL-no: 01.001 and 01.046] or its metabolites are not endogenous.
Step A5
The two candidate substances [FL-no: 01.001 and 01.046] are supported by the substance [FL-no:
01.045] for which an adequate carcinogenicity study is available. From this study a no observed
adverse effect level (NOAEL) of 215 mg/kg bw per day can be derived. The estimated daily per capita
intake is 4000 µg for [FL-no: 01.001] and 2100 µg for [FL-no: 01.046], corresponding to 0.07 mg/kg
bw per day and 0.035 mg/kg bw per day at a body weight of 60 kg, respectively. Thus, a margin of
safety of 3070 can be calculated for [FL-no: 01.001] and a margin of safety of 6140 can be calculated
for [FL-no: 01.046]. These two substances are accordingly not expected to be of safety concern at the
estimated levels of intake.
Step B3
The four candidate substances [FL-no: 01.035, 0.059, 01.064 and 01.070] proceeding via the B-side
and which have been assigned to Cramer structural class I have estimated European daily per capita
intakes between 0.0085 and 14 µg (Table 12). These intakes are below the threshold of concern of
1800 µg/person per day for structural class I. Accordingly, these four substances all proceed to step B4
of the Procedure.
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Step B4
For one of these substances, 4(10)-thujene [FL-no: 01.059] a margin of safety could be calculated
based upon a NOAEL (222 mg/kg bw) for the supporting substance ß-caryophyllene [FL-no: 01.007].
Compared to the MSDI of 4(10)-thujene of 14 µg/capita per day equal to 0.2 µg/kg bw per day, the
NOAEL provides a margin of safety of 9.5 x 105.
For the three remaining substances, 2,6-dimethylocta-2,4,6-triene [FL-no: 01.035], cis-3,7-dimethyl-
1,3,6-octatriene [FL-no: 01.064] and 1-octene [FL-no: 01.070] a margin of safety could be calculated
based upon a NOAEL (44 mg/kg bw) for the supporting substance myrcene [FL-no: 01.008].
Compared to the MSDI of 2,6-dimethylocta-2,4,6-triene [FL-no: 01.035], cis-3,7-dimethyl-1,3,6-
octatriene [FL-no: 01.064] and 1-octene [FL-no: 01.070] of 9.1, 14 and 0.0085 µg/capita per day
equal to 0.15, 0.23 and 0.00014 µg/kg bw per day, the NOAEL provides a margin of safety of 2.9 x
105, 1.9 x 105 and 3.1 x 108.
The stepwise evaluations of the 14 substances are summarised in Table 12: Summary of Safety
Evaluation by the EFSA (FGE.25Rev3).
6.3. EFSA Considerations
In FGE.78Rev1, the information on myrcene came from FGE.25Rev2, in which data on myrcene have
been evaluated in detail. Based on the toxicity study of myrcene, available at that time, it was
concluded in FGE.25Rev2 that: “No overall NOAEL from the NTP study on myrcene could be
allocated due to the observation renal toxicity in male and female rats at all dose groups. The Panel
has considered deriving a BMDL (benchmark dose level) from the NTP study of myrcene. However, a
BMDL from this study could not be derived since nearly 100 % incidence of nephropathy was
observed in male rats already at the lowest dose of myrcene. Since then, new toxicity data have
become available (Bauter, 2013b) and a no-adverse-effect level (NOAEL) for administration of
myrcene in the diet to rats was calculated to provide an estimated daily intake of 44 mg/kg bw per day
for males and 53 mg/kg bw per day for females, respectively.
The 21 JECFA evaluated hydrocarbons and the 14 EFSA evaluated hydrocarbons are distributed into
subgroups of structurally related substances by EFSA. The Panel conclusions on predictions of
metabolism are shown in Table 4 below.
Table 4: Subgroups as Classified by EFSA within the Groups of the JECFA evaluated
Hydrocarbons (JECFA, 2006a) and the EFSA evaluated Hydrocarbons in FGE.25Rev3 (EFSA CEF
Panel, in press). The JECFA evaluated Hydrocarbons are Listed in Brackets.
FL-no EU Register name Structural formula Struc.
class
Predicted
metabolism to
innocuous
products?
(by EFSA)
A- or B-
side of the
Procedure
(EFSA)
A- or B- side
of the
Procedure
(JECFA)
I: ACYCLIC ALKANES
01.033 2,2-Dimethylhexane I Yes A
01.034 2,4-Dimethylhexane I Yes A
01.038 Dodecane I Yes A
01.054 Pentadecane I Yes A
01.057 Tetradecane I Yes A
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II: ACYCLIC ALKENES
01.035 2,6-Dimethylocta-2,4,6-triene I No (lack of supporting
data)
B
01.064 cis-3,7-Dimethyl-1,3,6-
octatriene
I No (presence of
terminal double bond
which may give rise to
reactive metabolites
without counteracting
metabolic options)
B
01.070 1-Octene I No (presence of
terminal double bond
which may give rise to
reactive metabolites
without counteracting
metabolic options)
B
(01.008) (Myrcene) I No (lack of supporting
data)
B A
(01.018) (β-Ocimene) I No (lack of supporting
data)
B A
(01.040) (α-Farnesene) I No (lack of supporting
data)
B A
(01.061) (Undeca-1,3,5-triene) I No (lack of supporting
data)
B A
III: CYCLOHEXENE HYDROCARBONS
01.001 Limonene I Yes A
01.046 l-Limonene I Yes A
01.027 Bisabola-1,8,12-triene I Yes A
01.028 β-Bisabolene I Yes A
01.039 δ-Elemene I Yes A
(01.005) (Terpinolene) I A A
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(01.006) (α-Phellandrene) I A A
(01.016) (1,4(8),12-Bisabolatriene) I A A
(01.019) (α-Terpinene) I A A
(01.020) (gamma-Terpinene) I A A
(01.045) (d-Limonene) I A A
(01.077) (1-Methyl-1,3-
cyclohexadiene)
I A A
IV: AROMATIC HYDROCARBONS
IVb: NAPHTHALENE HYDROCARBONS
IVe: ALKYL SUBSTITUTED BENZENE HYDROCARBONS
(01.002) (1-isopropyl-4-
methylbenzene)
I A A
(01.010) (1-isopropenyl-4-
methylbenzene)
I No B A
V: BI- and TRICYCLIC, NONAROMATIC HYDROCARBONS
01.059 4(10)-Thujene No (but supported by
01.007)
B
(01.003) (Pin-2(10)-ene) I No (but supported by
01.007)
B A
(01.004) (Pin-2(3)-ene) I No (but supported by
01.007)
B A
(01.007) (β-Caryophyllene) I No (but supported by
01.007)
B A
(01.009) (Camphene) I No (but supported by
01.007)
B A
(01.017) (Valencene) I No (but supported by
01.007)
B A
(01.024) (β-Bourbonene) H
H H
I No (but supported by
01.007)
B A
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(01.026) (1(5),7(11)-Guaiadiene) I No (but supported by
01.007)
B A
(01.029) (δ-3-Carene) I No (but supported by
01.007)
B A
The Panel agrees with the application of the Procedure as performed by the JECFA for seven
substances in the subgroup III (Cyclohexene hydrocarbons) and one substance in subgroup IVe (Alkyl
substituted benzene hydrocarbons) [FL-no: 01.002, 01.005, 01.006, 01.016, 01.019, 01.020, 01.045
and 01.077], which all are evaluated via the A-side of the Procedure with the conclusion “no safety
concern at estimated levels of intake based on the MSDI approach”.
For the remaining 14 substances which were all predicted to be metabolised to innocuous products
(evaluated via the A-side of the Procedure) by the JECFA the Panel does not agree with the way the
JECFA applied the Procedure for the evaluation of Flavouring Substances.
For four substances in subgroup II [FL-no: 01.008, 01.018, 01.040 and 01.061]: Acyclic alkenes, it
could not be anticipated that the substances would be metabolised to innocuous products due to
presence of terminal double bond which may give rise to reactive metabolites without counteracting
metabolic options. In a 90 day study in rats by Bauter (Bauter, 2013b) on the representative substance
myrcene [FL-no: 01.008] a NOAEL of 44 mg/kg bw per day could be established. Compared to the
MSDI of myrcene of 290 µg/capita per day equal to 4.8 µg/kg bw per day, the NOAEL provides a
margin of safety (MOS) of 9200. The MOS for [FL-no 01.018, 01.040 and 01.061] based upon the
NOAEL for myrcene are 4.8x105, 4.4x106 and 1.1x107, respectively. The Panel agrees that this
provides sufficient safety margins and that these flavouring substances can be evaluated at step B4 in
the Procedure as being of no safety concern.
For one substance (1-isopropenyl-4-methylbenzene, [FL-no: 01.010]) in subgroup IVe: Alkyl
substituted benzenes, it could not be anticipated that the substance would be metabolised to innocuous
products due to presence of terminal double bond which may give rise to reactive metabolites without
counteracting metabolic options. In a 90 day study in rats by Posternak et al. (Posternak et al., 1969)
NOAEL 0.625 mg/kg bw per day could be established. Compared to the MSDI of 18 µg/capita per
day ~ 0.3 µg/kg bw per day, the NOAEL provides a margin of safety of 2000.
For eight substances in subgroup V [FL-no: 01.003, 01.004, 01.007, 01.009, 01.017, 01.024, 01.026
and 01.029]: Bi- and tricyclic, nonaromatic hydrocarbons, no data are available to conclude that the
substances will be metabolised to innocuous products. In a 90 day study in rats by Bauter (Bauter,
2013a) on the representative substance ß-caryophyllene [FL-no: 01.007] a NOAEL of 222 mg/kg bw
per day could be established. Compared to the MSDI of ß-caryophyllene of 330 µg/capita per day
equal to 5.5 µg/kg bw per day, the NOAEL provides a margin of safety of 40 000. The margin of
safety for [FL-no 01.003, 01.004, 01.009, 01.017, 01.024, 01.026 and 01.029] based upon the
respective MSDI for these substances and the NOAEL for ß-caryophyllene, range between 7400 and
1.1x107. The Panel agrees that this provides sufficient safety margins and that these flavouring
substances can be evaluated at step B4 in the Procedure as being of no safety concern.
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CONCLUSION
The present Revision of FGE.78, FGE.78Rev2, includes the assessment of additional available toxicity
data for β-caryophyllene [FL-no: 01.007] and myrcene [FL-no: 01.008]. The data provided are for 
both substances a 90-day study. Furthermore, new short term study and genotoxicity data have been
provided for [FL-no: 01.007].
The Panel concluded that the 21 substances in the JECFA flavouring groups of aliphatic and alicyclic
and aromatic hydrocarbons are structurally related to the group of 14 aliphatic hydrocarbons evaluated
by EFSA in the Flavouring Group Evaluation 25, Revision 3 (FGE.25Rev3).
The Panel agrees with the application of the Procedure as performed by the JECFA for eight of the 21
substances considered in this FGE [FL-no: 01.002, 01.005, 01.006, 01.016, 01.019, 01.020, 01.045
and 01.077].
For the following 13 substances [FL-no: 01.003, 01.004, 01.007, 01.008, 01.009, 01.010, 01.017,
01.018, 01.024, 01.026, 01.029, 01.040 and 01.061] it cannot be concluded that they are metabolised
to innocuous substances and therefore their evaluation should proceed along the B-side of the
Procedure. For one of these substances, 1-isopropenyl-4-methylbenzene [FL-no: 01.010] from
subgroup IVe (alkyl substituted benzene hydrocarbons), a NOAEL was available giving an adequate
margin of safety compared to the estimated level of intake.
For eight substances [FL-no: 01.003, 01.004, 01.007, 01.009, 01.017, 01.024, 01.026 and 01.029]
adequate margins of safety compared to the estimated levels of intake were estimated based upon a
NOAEL from a 90-day study in rats, for the representative substance ß-caryophyllene [FL-no:
01.007]. The NOAEL of 222 mg/kg bw per day provides a margin of safety of 40 000 for ß-
caryophyllene. The margins of safety for [FL-no: 01.003, 01.004, 01.009, 01.017, 01.024, 01.026 and
01.029] based upon the respective MSDI for these substances and the NOAEL for ß-caryophyllene,
range between 7400 and 1.1x107. The Panel agrees that this provides sufficient safety margins and that
these flavouring substances can be evaluated at step B4 in the Procedure as being of no safety concern.
For four substances [FL-no: 01.008, 01.018, 01.040 and 01.061] adequate margins of safety compared
to the estimated levels of intake were estimated based upon a NOAEL from a 90-day study in rats, for
the representative substance myrcene [FL-no: 01.008]. The NOAEL of 44 mg/kg bw per day provides
a margin of safety of 9100 for myrcene. The margins of safety for [FL-no 01.018, 01.040 and 01.061]
based upon the respective MSDI for these substances and the NOAEL for myrcene are 4.8x105,
4.4x106 and 1.1x107, respectively. The Panel agrees that this provides sufficient safety margins and
that these flavouring substances can be evaluated at step B4 in the Procedure as being of no safety
concern.
For two substances use levels have been provided by the Industry [FL-no: 01.008 and 01.026]. The
mTAMDI figures calculated were above the threshold of concern for both of these substances for
which more reliable exposure data are needed. On the basis of such additional data [FL-no: 01.008 and
01.026] should be reconsidered using the Procedure. For the remaining 19 substances evaluated
through the Procedure use levels are needed to calculate the mTAMDIs in order to identify those
flavouring substances that need more refined exposure assessment to finalise the evaluation.
In order to determine whether the conclusion for the 21 JECFA evaluated substances can be applied to
the materials of commerce, it is necessary to consider the available specifications.
Adequate specifications including complete purity criteria and identity are available for all 21 JECFA
evaluated substances.
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Thus, for the 21 substances15 [FL-no: 01.002, 01.003, 01.004, 01.005, 01.006, 01.007, 01.008, 01.009,
01.010, 01.016, 01.017, 01.018, 01.019, 01.020, 01.024, 01.026, 01.029, 01.040, 01.045, 01.061 and
01.077] the Panel agrees with the JECFA conclusion “no safety concern at estimated levels of intake
as flavouring substances” based on the MSDI approach.
15 The 22nd substance, 1-methylnaphthalene [FL-no: 01.014] is in the process of being deleted from the Union List (DG
SANTE, 2015).
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SUMMARY OF GENOTOXICITY DATA
Table 5: Genotoxicity Data (in vitro / in vivo) for Aliphatic and Alicyclic Hydrocarbons (JECFA, 2006a)
FL-no
JECFA-no
EU Register name
JECFA name
Structural formula End-point Test system Concentration Results Reference
In vitro
01.009
1323
Camphene Reverse mutation S. typhimurium
TA98, TA100
0.05–100 μl/plate  
(42.1–84,200 μg/plate)1
Negativeb (Rockwell and Raw, 1979)
Reverse mutation S. typhimurium
TA98, TA100,
UTH8413, UTH8414
10–1000 μg/plate  Negativec (Connor et al., 1985)
Sister chromatid
exchange
Chinese hamster
ovary K-1 cells
10–1000 μmol/l  
(1.4–136.2 μg/ml)d,e
Negativef (Sasaki et al., 1989)
01.007
1324
β-Caryophyllene Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537, TA1538
0.1–150 μl/plate  
(90.4–135 525 μg/plate)g
Negativec (Jagannath, 1984a)
Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537, TA1538
Up to 150 000 μg/plate  Negativec (Heck et al., 1989)
Reverse mutation S. typhimurium
TA97, TA98, TA100,
TA1535
3.3–333 μg/plate -S9h
1–10 000 μg/plate +S9h
Negativec (NTP, 2004b)
Sister chromatid
exchange
Chinese hamster
ovary K-1 cells
10–1000 μmol/l  
(2.0–204.4 μg/ml)i,e
Negativef (Sasaki et al., 1989)
Unscheduled
DNA synthesis
Rat hepatocytes Up to 10 000 μg/ml  Negative (Heck et al., 1989)
01.045
1326
d-Limonene Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537
0.03–30 μmol/plate  
(4.1–4087 μg/plate)k,l
Negativec (Florin et al., 1980)
Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537
0.3–33 μg/plate -S9;  
10–3333 μg/plate +S9  
Negativec (Haworth et al., 1983; NTP, 1990)
Reverse mutation S. typhimurium
TA98, TA100,
UTH8413, UTH8414
10–500 μg/plate  Negativec (Connor et al., 1985)
Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537, TA1538
Up to 150 000 μg/plate  Negativec (Heck et al., 1989)
Reverse mutation S. typhimurium
TA102
Up to 5 000 μg/plate  Negativeb (Müller et al., 1993)
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Table 5: Genotoxicity Data (in vitro / in vivo) for Aliphatic and Alicyclic Hydrocarbons (JECFA, 2006a)
FL-no
JECFA-no
EU Register name
JECFA name
Structural formula End-point Test system Concentration Results Reference
Forward mutation,
(non-)reciprocal
recombination
Saccharomyces
cerevisiae MP1
Up to 230 mmol/l
(31 335 μg/ml)k
Negativef (Fahrig, 1984)
Forward mutation Mouse lymphoma
L5178Y Tk+/- cells
Up to 100 μg/ml  Negativec (Heck et al., 1989)
Forward mutation Mouse lymphoma
L5178Y Tk+/- cells
Up to 100 μg/mlm Negativec (Myhr et al., 1990; NTP, 1990)
Sister chromatid
exchange
Chinese hamster
ovary K-1 cells
10–333 μmol/l  
(1.4–45.4 μg/ml)k,e
Negativef (Sasaki et al., 1989)
Sister chromatid
exchange
Chinese hamster
ovary cells
15–162 μg/ml -S9;  
16.2–162 μg/ml +S9  
Negativec (Anderson et al., 1990; NTP, 1990)
Chromosomal
aberration
Chinese hamster
ovary cells
10–100 μg/ml -S9;  
50–500 μg/ml +S9  
Negativec (Anderson et al., 1990; NTP, 1990)
Cell
transformation
Syrian hamster
embryo cells
0.1–100 μg/ml  Negative (Pienta, 1980)
Cell
transformation
Syrian hamster
embryo cells
0.1–3 mmol/l
(13.6–408.7 μg/ml)k
Positiven (Rivedal et al., 2000)
01.008
1327
Myrcene Reverse mutation S. typhimurium
TA97, TA98,
TA100, TA1535
33–3 333 μg/plate -S9o;
33–10 000 μg/plate +S9o
Negativec (NTP, 2004c)
Gene mutation Chinese hamster
V79 Hprt cells
100–1 000 μg/ml  Negativec (Kauderer et al., 1991)
Sister chromatid
exchange
Human
lymphocytes
100–1 000 μg/ml  Negativec (Kauderer et al., 1991)
Sister chromatid
exchange
Chinese hamster
V79 cells
100–500 μg/ml -S9;  
500 μg/ml +S9  
Negativec (Röscheisen et al., 1991)
Sister chromatid
exchange
Hepatic tumour
cells
100–500 μg/ml  Negativep (Röscheisen et al., 1991)
Chromosomal
aberration
Human
lymphocytes
100–1 000 μg/ml  Negativec (Kauderer et al., 1991)
01.006
1328
α-Phellandrene Sister chromatid
exchange
Chinese hamster
ovary K-1 cells
33.3–1 000 μmol/l  
(4.5–136.2 μg/ml)q
Negativef (Sasaki et al., 1989)
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Table 5: Genotoxicity Data (in vitro / in vivo) for Aliphatic and Alicyclic Hydrocarbons (JECFA, 2006a)
FL-no
JECFA-no
EU Register name
JECFA name
Structural formula End-point Test system Concentration Results Reference
01.004
1329
Pin-2(3)-ene Reverse mutation S. typhimurium
TA98, TA100
0.05–100 μl/plate  
(43–85 920 μg/plate)r
Negativeb (Rockwell and Raw, 1979)
Reverse mutation S. typhimurium
TA98, TA100,
TA1535, TA1537
0.03–30 μmol/plate  
(4.1–4 087 μg/plate)s,l
Negativec (Florin et al., 1980)
Reverse mutation S. typhimurium
TA98, TA100, TA1535, TA1537,
TA1538
0.1–25 μl/plate  
(85.9–21 480 μg/plate)r,t
Negativec (Jagannath, 1984a)
Reverse mutation S. typhimurium
TA98, TA100,
UTH8413, UTH8414
10–500 μg/plate  Negativec (Connor et al., 1985)
Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537, TA1538
Up to 25 000 μg/plate  Negativec (Heck et al., 1989)
Unscheduled
DNA synthesis
Rat hepatocytes Up to 10 000 μg/ml  Negative (Heck et al., 1989)
01.003
1330
Pin-2(10)-ene Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537
0.03–30 μmol/plate  
(4.1–4 087 μg/plate)u,v
Negativec (Florin et al., 1980)
Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537, TA1538
0.01–5 μl/plate  
(8.6–4 320 μg/plate)w,x
Negativec (DeGraff, 1983)
Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537, TA1538
Up to 5 000 μg/plate  Negativec (Heck et al., 1989)
Sister chromatid
exchange
Chinese hamster
ovary K-1 cells
33.3–1 000 μmol/l  
(4.5–136.2 μg/ml)u
Negativef (Sasaki et al., 1989)
01.020
1340
gamma-Terpinene Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537, TA1538
Up to 50 000 μg/plate  Negativec (Heck et al., 1989)
Unscheduled
DNA synthesis
Rat hepatocytes Up to 30 μg/ml  Negative (Heck et al., 1989)
01.029
1342
δ-3-Carene Reverse mutation S. typhimurium
TA98, TA100, TA102
1.25–5 μl/plate  
(2157–4 314 μg/plate)y
Positivez (Kurttio et al., 1990)
1346 Cadinene, not in Register Reverse mutation S. typhimurium
TA97, TA98, TA100,
TA1535, TA1537
1–100 μg/plate -S91;
100–10 000 μg/plate +S91
Negative;
Positive2
(NTP, 2004d)
Reverse mutation S. typhimurium
TA98, TA100, TA1535,
TA1537
10–3 333 μg/plate -S9;  
100–10 000 μg/plate +S9o
Negativec (Haworth et al., 1983; NTP, 2004e)
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Table 5: Genotoxicity Data (in vitro / in vivo) for Aliphatic and Alicyclic Hydrocarbons (JECFA, 2006a)
FL-no
JECFA-no
EU Register name
JECFA name
Structural formula End-point Test system Concentration Results Reference
Forward mutation Mouse lymphoma
L5178Y Tk+/- cells
0.005–0.05 μg/ml -S9  
(4.6–46.2 μg/ml)4,5;
0.01–0.08 μl/ml +S9  
(9.2–73.9 μg/ml)4,6
Negativec (NTP, 2004f)
Sister chromatid
exchange
Chinese
hamster ovary cells
8.9–26.6 μg/ml -S9;  
22.2–31.1 μg/ml +S9  
Equivocal;
Negative
(NTP, 2004g)
Chromosomal
aberration
Chinese hamster
ovary cells
24.9–35.5 μg/ml -S9;  
30.2–40 μg/ml +S9  
Negativec (NTP, 2004g)
In vivo
01.045
1326
d-Limonene Mammalian spot
test
Mouse (C57BLxT)
embryos
215 mg/kg bw7 Negative (Fahrig, 1984)
01.008
1327
Myrcene Chromosomal
aberration
Rat bone
marrow cells
100–1 000 mg/kg bw8 Negative9 (Zamith et al., 1993)
Micronucleus
formation
Mouse
peripheral blood
250–2 000 mg/kg bw10 Negative (NTP, 2004h)
a Calculated using a density of camphene of 0.842 g/ml (Lewis, 1999).
b With metabolic activation.
c With and without metabolic activation.
d Calculated using relative molecular mass of camphene of 136.24.
e Cytotoxicity observed at the highest dose/concentration tested.
f Without metabolic activation.
g Calculated using a density of β-caryophyllene of 0.9035 (0.897 - 0.910) g/ml (Lewis, 1999). 
h Precipitation or slight toxicity was occasionally observed at the higher concentrations tested.
i Calculated using relative molecular mass of β-caryophyllene of 204.36. 
j Isomer not specified.
k Calculated using relative molecular mass of d-limonene of 136.24.
l Cytotoxicity and precipitation observed at doses > 3 μmol/plate. 
m In some trials concentrations ≥ 50 μg/ml were lethal.
n Although not statistically significant (p = 0.089), a fourfold increase in transformation frequency was observed.
o Slight toxicity was occasionally observed at the highest concentration tested.
p Slight increase in sister chromatid exchanges, which was reproducible but not dose-dependent.
q Calculated using relative molecular mass of α-phellandrene of 136.24. 
r Calculated using a density of a-pinene of 0.8592 g/ml (Lewis, 1999).
s Calculated using relative molecular mass of α-pinene of 136.24. 
t Cytotoxicity observed at doses of 2.5 to 25 μg/plate, depending on the different tester strains.
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u Calculated using relative molecular mass of β-pinene of 136.24. 
v Cytotoxicity observed at doses > 3 μmol/plate.
w Calculated using a density of β-pinene of 0.864 g/ml (Lewis, 1999). 
x Cytotoxicity observed at doses of 2.5 to 5 μl/plate, depending on the different tester strains. 
y Calculated using a density of d-3-carene of 0.8627 (0.8586 - 0.8668) g/ml (Merck, 1996).
z Positive without metabolic activation in TA100 and TA102 at doses ≥ 2.5 μl/plate; negative with metabolic activation in all strains. 
1. Slight toxicity was observed at various doses.
2. Equivocal/weak positive only in TA97 and TA100 with metabolic activation.
3. β-Cadinene was tested. 
4. Calculated using a density of β-cadinene of 0.9239 g/ml (Merck, 1996). 
5. The highest concentration of 0.05 μl/ml was lethal. 
6. In some trials, concentrations ≥ 0.04 μl/ml were lethal. 
7. Administered via injection into the peritoneal cavity of the dam.
8. Administered via gavage.
9. A dose-related increase in mitotic index was observed, but no clastogenicity.
10. Administered via gavage for 90 days.
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Table 6: Genotoxicity Data (in vitro / in vivo) for Aromatic Hydrocarbons (JECFA, 2006a)
FL-no
JECFA-
no
EU Register name
JECFA name
Structural formula End-point Test system Concentration Results Reference
01.002
1325
1-Isopropyl-4-methylbenzene Reverse mutation S. typhimurium
TA98, TA100
0.05–100 μl/plate  
(42.7–85 300 μg/  
plate)a
Negativeb (Rockwell and Raw, 1979)
a Calculated using a density of p-cymene of 0.853 g/ml (Lewis, 1999).
b With metabolic activation.
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Table 7: Genotoxicity Data (in vitro) EFSA / FGE.25Rev3 (EFSA CEF Panel, in press)
Chemical Name [FL-no]* Test System Test Object Concentration Result Reference Comments
Cedrene washed6
[CAS no 11028-42-5]
Ames test S. typhimurium
TA97, TA98; TA100; TA1535; TA102
8-50004 Negative1 (Gocke, 1999) Validity cannot be evaluated as substance is
not specified.
Cedarwood oil terpenes and tertonoids.
Ames test S. typhimurium
TA97, TA98; TA100; TA1535; TA102
1.6-10005 Negative1 (Gocke, 1999) Validity cannot be evaluated as substance is
not specified.
Cedarwood oil terpenes and tertonoids.
Dodecane [01.038] Ames test S. typhimurium
TA98; TA100
NR Negative1 (Tummey et al., 1992) Only part of abstract available. Validity of
the study cannot be evaluated due to
insufficient report of experimental details
and results.
Mammalian cell gene
mutation test (mouse
lymphoma assay)
Mouse lymphocytes NR Negative1 (Tummey et al., 1992) Only part of abstract available. Validity of
the study cannot be evaluated due to
insufficient report of experimental details
and results.
Mammalian cell gene
mutation test
V79 Chinese hamster ovary cells 0.12 mM (20 µg/ml) Negative3 (Lankas et al., 1978) Published non-GLP study. Some important
details of study design and results are not
reported. Thus, the validity of the study
cannot be evaluated. Study designed to
evaluate the ability of various alkanes to
enhance the mutagenicity induced by the
chemical carcinogen methylazoxymethanol
acetate. Dodecane showed no mutagenic
activity per se, but increased the
mutagenesis induced by pretreatment with
the carcinogen.
Tetradecane [01.057] Ames test S. typhimurium
TA98; TA100; TA1535; TA1537; TA1538
50, 150, 500, 1500,
5000 µg/plate
Negative1 (PETRESA, 19??a) (Study carried out by Huntingdon Research
Centre, Report PEQ 5C/85914, sponsored
by PETRESA; year not indicated)
Unpublished GLP-study carried out in
accordance with OECD guideline 471 as
stated in the IUCLID datasheet submitted.
IUCLID abstract available only. Validity of
the study cannot be evaluated.
Mammalian cell gene
mutation test
V79 Chinese hamster ovary cells 0.12 mM (23 µg/ml) Negative3 (Lankas et al., 1978) Published non-GLP study. Some important
details of study design and results are not
reported. Thus, the validity of the study
cannot be evaluated. Study designed to
evaluate the ability of various alkanes to
enhance the mutagenicity induced by the
chemical carcinogen methylazoxymethanol
acetate. Tetradecane showed no mutagenic
activity per se, but increased the
mutagenesis induced by pretreatment with
the carcinogen.
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Table 7: Genotoxicity Data (in vitro) EFSA / FGE.25Rev3 (EFSA CEF Panel, in press)
Chemical Name [FL-no]* Test System Test Object Concentration Result Reference Comments
Ames test
(preincubation method)
S. typhimurium
TA98; TA100; UTH8414; UTH8413
0, 50, 100, 500, 1000,
2000 µg/plate
Negative1 (Connor et al., 1985) Published non-GLP study with insufficient
report of some details of method and
results. Thus, the validity of the study
cannot be evaluated. Cytotoxicity not
reported.
(2-Methylbuta-1,3-diene) Ames test S. typhimurium
TA98; TA100; TA1530; TA1535; TA1538
25 % atmosphere
concentration
Negative1 (De Meester et al., 1981) Published non-GLP study not in accordance
with OECD guideline 471. Part of a larger
study evaluating the effects of various
experimental conditions (different liver cell
preparations and concentrations) on the
mutagenic activity of butadiene,
hexachlorobutadiene and isoprene. Some
important details of study design and results
are not reported. Thus, the validity of the
study cannot be evaluated. Plates were
exposed to a 25 % 2-methylbuta-1,3-diene
atmosphere for 24 hours.
Ames test
(preincubation method)
S. typhimurium
TA98; TA100; TA1535; TA1537
0, 100, 333, 1000,
3333, 10000 µg/plate
Negative1 (Mortelmans et al., 1986)
(NTP, 1999)
Published summary report including
detailed results from studies on 270
compounds tested in various laboratories
within the NTP to a large extent in
accordance with OECD guideline 471.
Ames test S. typhimurium
TA102; TA104
NR Negative (Kushi et al., 1985) Published abstract only, of which part of
the text including results is missing. No
information on the use of a metabolic
activation system. Validity of the study
cannot be evaluated.
Ames test
(preincubation method)
S. typhimurium
TA98; TA100; TA1535
E. coli WP2uvrA/pKM101
0, 500, 1000, 2000,
5000 µg/plate
Negative1 (Madhusree et al., 2002) Published non-GLP study with limited
report of experimental details and results.
Thus, the validity of the study cannot be
evaluated.
Sister chromatid exchange
test
Chinese hamster ovary cells 0, 50, 160, 500, 1600
µg/ml (-S9)
0, 160, 500, 1600, 5000
µg/ml (+S9).
Negative1 (NTP, 1999; Galloway et al.,
1987)
Published summary report including
detailed results from studies on 108
chemicals tested within the NTP to a large
extent in accordance with OECD guideline
479.
Chromosomal aberration
assay
Chinese hamster ovary cells 0, 1600, 3000, 5000
µg/ml
Negative1 (NTP, 1999; Galloway et al.,
1987)
Published summary report including
detailed results from studies on 108
chemicals tested within the NTP to a large
extent in accordance with OECD guideline
473.
(Myrcene [01.008]) Chromosomal aberration
assay
Human lymphocytes 1000 µg/ml Negative1 (Kauderer et al., 1991) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Mammalian cell gene
mutation assay
Chinese hamster ovary V79 cells 1000 µg/ml Negative1 (Kauderer et al., 1991) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Sister chromatid exchange
test
Human lymphocytes 1000 µg/ml Negative1 (Kauderer et al., 1991) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
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Table 7: Genotoxicity Data (in vitro) EFSA / FGE.25Rev3 (EFSA CEF Panel, in press)
Chemical Name [FL-no]* Test System Test Object Concentration Result Reference Comments
Sister chromatid exchange
test
Chinese hamster ovary cells and hepatic
tumour cell line
500 µg/ml Negative1 (Röscheisen et al., 1991) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test
(plate incorporation method)
S. typhimurium TA97a ; TA98; TA100;
TA1535
Up to 1500 µg/plate
(16 concentrations)
Negative (Gomes-Carneiro et al., 2005) Valid studies which were carried out with a
selection of 6 of the the concentrations
mentioned. In the first run concentrations
up to cytotoxicity were studied; in a second
run only non-toxic concentrations were
tested.
Ames S. typhimurium TA97; TA98; TA100;
TA1535
10 – 10 000 µg/plate Negative1 (NTP, 2010)
Reverse mutation E. coli WP2uvrA/pKM101 50 – 10 000 µg/plate Negative1 (NTP, 2010)
Ames S. typhimurium TA97a; TA98; TA100;
TA1535
10 - 5000 Negative1 (Gomes-Carneiro et al., 2005)
Ames S. typhimurium TA97a; TA98; TA100;
TA1535
1 - 1500 Negative1 (Gomes-Carneiro et al., 2005)
(d-Limonene [01.045]) Ames test
(preincubation method)
S. typhimurium
TA98; TA100; TA1535; TA1537
0.03, 0.3, 3, 30
µM/plate
(4.1, 41, 410, 4100
µg/plate)
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test S. typhimurium
TA98; TA100; TA1535; TA1537; TA1538
Up to 150,000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test S. typhimurium TA102 Up to 5000 µg/plate Negative1 (Müller et al., 1993) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test S. typhimurium TA98; TA100; TA1535;
TA1537
Up to 3333 µg/plate Negative1 (Haworth et al., 1983) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test
(preincubation method)
S. typhimurium
TA98; TA100, UTH8413 and UTH8414
0, 10 to 500 µg/plate
(5 concentrations)
Negative1 (Connor et al., 1985) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Forward mutation assay L5178Y Mouse
lymphoma
Up to 100 µg/ml Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Forward mutation assay L5178Y Mouse Lymphoma Up to 100 µg/ml Negative1 (Myhr et al., 1990) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Chromosomal aberration
assay
Chinese hamster
ovary cells
500 µg/ml Negative1 (Anderson et al., 1990) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Sister chromatid exchange
test
Chinese hamster ovary cells 162 µg/ml Negative1 (Anderson et al., 1990) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Sister chromatid exchange
test
Chinese hamster ovary cells 1000 µM
(136.2 µg/ml)
Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
(gamma-Terpinene [01.020]) Ames test S. typhimurium TA98; TA100; TA1535;
TA1537; TA1538
50,000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Unscheduled DNA synthesis Rat hepatocytes 30 µg/ml Negative (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
(α-Terpinene [01.019]) Ames test
(plate incorporation method)
S. typhimurium TA97a ; TA98; TA100;
TA1535
Up to 1500 µg/plate
(13 concentrations)
Negative (Gomes-Carneiro et al., 2005) Valid studies which were carried out with a
selection of 6 of the the concentrations
mentioned. In the first run concentrations
up to cytotoxicity were studied; in a second
run only non-toxic concentrations were
tested.
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Table 7: Genotoxicity Data (in vitro) EFSA / FGE.25Rev3 (EFSA CEF Panel, in press)
Chemical Name [FL-no]* Test System Test Object Concentration Result Reference Comments
(α–Phellandrene [01.006]) Sister chromatid exchange
test
Chinese hamster ovary cells 1000 µM(136.2 µg/ml) Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
(δ-3-Carene [01.029])  Ames test
(plate incorporation method)
S. typhimurium TA98; TA100; TA102 up to 5 µl/plate
(up to 4300 µg/plate; 5
concentrations)
Positive3
Negative2
(Kurttio et al., 1990) Published non-GLP study with
insufficiently reported results. Limited
validity. Positive without metabolic
activation in TA100 and TA102 and at
doses of 2.5 µl/plate and higher.
(Pin-2(3)-ene [01.004]) Ames test S. typhimurium
TA98; TA100
100 µl/plate
(85,800 µg/ plate)
Negative2 (Rockwell and Raw, 1979) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test S. typhimurium TA98; TA100; TA1535;
TA1537
0.03, 0.3, 3, 30
µM/plate
(4.1, 41, 410, 4100 µg/
plate)
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test S. typhimurium TA98; TA100; TA1535;
TA1537; TA1538
25000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test S. typhimurium TA98; TA100; TA1535;
TA1537; TA1538
25 µl/plate
(21,450 µg/ plate)
Negative1 (Jagannath, 1984a) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test S. typhimurium TA98; TA100; TA1535;
TA1537; TA1538
5 µl/plate
(4290 µg/plate)
Negative1 (DeGraff, 1983) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test S. typhimurium TA98; TA100; UTH8414;
UTH8413
0, 10 to 500 µg/plate
(5 concentrations)
Negative1 (Connor et al., 1985) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Unscheduled DNA synthesis Rat hepatocytes 10000 µg/ml Negative (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
(+)-α-pinene (pin-2(3)-ene) 
(isomer of [01.004])
Ames test
(plate incorporation method)
S. typhimurium TA97a ; TA98; TA100;
TA1535
Up to 1000 µg/plate
(18 concentrations)
Negative (Gomes-Carneiro et al., 2005) Valid studies.
(-)-α-pinene (pin-2(3)-ene) 
(isomer of [01.004])
Ames test
(plate incorporation method)
S. typhimurium TA97a ; TA98; TA100;
TA1535
Up to 4000 µg/plate
(19 concentrations)
Negative (Gomes-Carneiro et al., 2005) Valid studies.
(Pin-2(10)-ene [01.003]) Ames test S. typhimurium TA98; TA100; TA1535;
TA1537; TA1538
5000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test
(preincubation method)
S. typhimurium
TA98; TA100; TA1535; TA1537
0.03, 0.3, 3, 30
µM/plate
(4.1, 41, 410, 4100
µg/plate)
Negative1 (Florin et al., 1980) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Sister chromatid exchange Chinese hamster ovary cells 1000 µM (136.2 µg/ml) Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
(Camphene [01.009]) Ames test S. typhimurium
TA98; TA100
100 µl/plate
(84,500 µg/ plate)
Negative2 (Rockwell and Raw, 1979) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test S. typhimurium TA98; TA100; UTH8414;
UTH8413
0, 10 to 1000 µg/plate
(5 concentrations)
Negative1 (Connor et al., 1985) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Sister chromatid exchange
test
Chinese hamster ovary cells 1000 µM (136.2 µg/ml) Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
(β–Caryophyllene [01.007]) Ames test S. typhimurium TA98; TA100; TA1535;
TA1537; TA1538
150,000 µg/plate Negative1 (Heck et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test S. typhimurium TA98; TA100; TA1535;
TA1537; TA1538
150 µl/plate Negative1 (Lorillard, 1984) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Ames test
(plate incorporation method)
S. typhimurium TA98; TA100; TA102;
TA1535; TA1537
10,000 µg/plate Negative1 (Longfellow, 1998) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
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Table 7: Genotoxicity Data (in vitro) EFSA / FGE.25Rev3 (EFSA CEF Panel, in press)
Chemical Name [FL-no]* Test System Test Object Concentration Result Reference Comments
Sister chromatid exchange
test
Chinese hamster ovary cells 1000 µM (204.4 µg/ml) Negative (Sasaki et al., 1989) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
* Supporting substances are listed in brackets.
NR: Not Reported
1 With and without S9 metabolic activation.
2 With metabolic activation.
3 Without metabolic activation
4 Plate incorporation
5 Pre-incubation
6 An Ames test with cedrene washed (unspecified cedrene) was also submitted, but an adequate identification of the substance studied was not possible. Therefore the study is not further
discussed
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Table 8: Genotoxicity Data (in vivo) EFSA / FGE.25Rev3 (EFSA CEF Panel, in press)
Chemical Name [FL-no]* Test System Test Object Route Dose Result Reference Comments
(2-Methylbuta-1,3-diene)
non-Register substance
In vivo Chromosomal
aberration assay
Mouse (B6C3F1) bone
marrow
(male mice)
Inhalation 0, 438, 1750, 7000
mg/kg feed for 6
hours per day for 12
exposures over a
period of 16 days
(Trial 1)
0, 70, 220, 700
mg/kg feed for 6
hours per day for 12
exposures over a
period of 16 days
(Trial 2)
Negative (Tice et al., 1987; Tice, 1988;
Shelby, 1990)
Unpublished study report and published
summary report of a valid multiple endpoint
cytogenicity study sponsered by NTP, roughly in
accordance with OECD guideline 475 (special
dosage regimen used).
In vivo Sister chromatid
exchange test
Mouse (B6C3F1) bone
marrow
(male mice)
Inhalation 0, 438, 1750, 7000
mg/kg feed for 6
hours per day for 12
exposures over a
period of 16 days
(Trial 1)
0, 70, 220, 700
mg/kg feed for 6
hours per day for 12
exposures over a
period of 16 days
(Trial 2)
Positive (Tice et al., 1987; Tice, 1988;
Shelby, 1990)
Unpublished study report and published
summary report of valid cytogenicity study
sponsered by NTP. The study is considered
valid.
Significant (0.01<p<0.05) increase in the
frequency of SCE in the bone marrow cells at all
concentrations. In addition, a significant delay in
bone marrow cellular proliferation kinetics
(lengthening of the generation time) was
detected. The mitotic index was not significantly
altered.
In vivo Micronucleus test Mouse (B6C3F1)
peripheral blood cells
(male mice)
Inhalation 0, 438, 1750, 7000
mg/kg feed for 6
hours per day for 12
exposures over a
period of 16 days
Positive (Tice et al., 1987; Tice, 1988) Unpublished study report and published
summary report of valid cytogenicity study
sponsored by NTP, roughly in accordance with
OECD guideline 474 (special dosage regimen
used). The study is considered valid.
Significant (p<0.001) increase in the frequency
of micronucleated polychromatic and
normochromatic erythrocytes, and percentage of
PCE. A significant (p<0.001) and dose-
dependent decrease in the percentage of
circulating polychromatic erythrocytes
(suppression of erythropoiesis) was noted.
In vivo Micronucleus test Rat lung fibroblasts
(male and female rats)
Inhalation 0, 220, 700, 7000
mg/kg feed for 13-
weeks
Negative (Khan and Heddle, 1991) Study carried out within NTP. Only tabulated
results available from NTP TR 486 (NTP, 1999).
Unusual study protocol. Validity of the study
cannot be evaluated.
(Myrcene [01.008]) In vivo Chromosomal
aberration assay
Rat (Wistar) bone
marrow
Gavage 0, 100, 500, 1000
mg/kg bw (single
exposure)
Negative (Zamith et al., 1993) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
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Chemical Name [FL-no]* Test System Test Object Route Dose Result Reference Comments
In vivo Micronucleus test Mouse (B6C3F1)
peripheral blood cells
Gavage 0, 250, 500, 1000,
2000 mg/kg bw
(single exposure)
Negative (NTP, 2003) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
Micronucleus assay Mouse peripheral
blood cells
Gavage 250, 500, 1000
mg/kg bw/ day
Negative (NTP, 2010)
(d-Limonene [01.045]) In vivo Comet assay Mouse (ddY) / Rat
(Wistar).
Oral 0, 2000 mg/kg Negative (Sekihashi et al., 2002) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
In vivo Mammalian spot
test
Mouse embryos from
C57BL/6JHan x T
stocks
Intraperitone
al injection
215 mg/kg bw Negative (Fahrig, 1984) Abstracted by JECFA at their 63rd meeting
(JECFA, 2006a).
In vivo Comet assay Rats (Sprague-
Dawley) (males)
(Kidneys)
Gavage 0, 1000, 2000 mg/kg
bw (single exposure)
Negative (Nesslany et al., 2007)
In vivo transgenic
mutagenisity assay
Rats (Big blue)
(males) (liver, kidney,
bladder)
Diet 0, 525 mg/kg bw per
day (10 days)
Negative (Turner et al., 2001) The author do not specify whether the tested
compound is d- or l-limonene, and the purity of
the compound is not stated. However, the
stability of the limonene in the diet was
measured.
Naphthalene [01.053] In vivo Unscheduled
DNA synthesis
Rat hepatocytes Gavage 0, 600, 1000, 1600
mg/kg bw
Negative (Research Toxicology Center,
1999)
Summarised report of unpublished study carried
out in accordance with OECD guideline 486.
Although some minor details of the results are
not reported (viability of cells, individual slide
values for nuclear grains and cytoplasmic grains)
the study is considered valid.
In vivo Micronucleus test Mouse (Swiss ICR)
bone marrow
Gavage 50, 250, 500 mg/kg
bw (single exposure)
Negative (Harper et al., 1984) Published non-GLP study not fully in
accordance with OECD guideline 474 (only
males tested, sampling time not indicated, effect
on PCE/NCE ratio not reported). Due to the
limited report of experimental details and results
the validity of the study cannot be evaluated.
At the dose of 500 mg/kg bw two of ten animals
died. The dose of 1500 mg/kg bw was toxic
(lethal) to all animals. Induction of micronuclei
in benzene-treated mice was significantly
enhanced by co-treatment with naphthalene at 50
and 250 mg/kg bw.
In vivo Micronucleus test Mouse (CD-1) bone
marrow
Intraperitone
al injection
250 mg/kg bw
(single exposure)
Negative (Sorg et al., 1985) Unpublished valid GLP-study carried in
accordance with OECD guideline 474.
Naphthalene was negative in the micronucleus
test at the dose of 250 mg/kg bw at all of the
time intervals tested. A harvest-time dependent
depression in the PCE/NCE ratio was observed
in animals treated with the test substance, which
was statistically significant (p ≤ 0.05) at sacrifice 
time of 72 hours.
* Supporting substances are listed in brackets.
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Table 9: Genotoxicity Data of β-Caryphyllene Submitted by EFFA (EFFA, 2012)  
FL-no
JECF
A-no
EU Register name
JECFA name
Structural formula End-point Test system Concentration Results Reference Comments
In vitro
01.007
1324
β-Caryophyllene Reverse mutation S. typhimurium
TA98, TA100,
E. coli
WP2uvrA
2300–9000
μg/plate
Negative1 (Di Sotto et al., 2008) Study not in compliance with OECD 471:
- assay does not include TA1535 and TA1537 (or
TA97, 97a, resp)
-5 concentrations tested (plate-incorpration) but not
given in detail
(authors stated that in range finder up to 9 mg/plate
without cytotoxicity)
-results not given in detail (no values, no raw data).
Methods and results poorly reported
-no historical contral data
insufficient quality.
In vivo
01.007
1324
β-Caryophyllene Micronucleated
polychromatic
erythrocytes
Mice 0, 20, 200 and
2000 mg/kg bw2
Negative (Molina-Jasso et al.,
2009)
In compliance with OECD 474
-except: number of micronucleated immature
erythrocytes not given separately for each animal;
historical controls not given.
Reliable with restrictions=limited validity.
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SUMMARY OF TOXICITY DATA
Table 10: Toxicity Data Considered by the Panel in FGE.78Rev2
Chemical Name
[FL-no:]
Species; Sex
No/group
Route Doses
(mg/kg bw per day)
Duration
(days)
NOAEL
(mg/kg bw per day)
Reference Comments
(Myrcene [01.008]) Rat; M, F
4/10
Diet 0, 8.0, 40 and 44 mg/kg bw per day
(males)
0, 9.6, 48 and 53 mg/kg bw per day
(females)
90 days 44 (males)
53 (females)
(Bauter, 2013b) No toxicity at highest dose level.
(β-Caryophyllene [01.007]) Rat; M, F
4/20
Diet 0, 222, 456 and 1.367 mg/kg bw per day
(males)
0, 263, 1.033 and 4.278 mg/kg bw per
day (females),
3 months 222 (males)
263(females)
(Bauter, 2013a) Study according to OECD Guideline
408.
Rat; M, F
4/6
Diet 0, 516, 1.547 and 3.569 mg/kg bw per
day (males)
0, 528, 1.582 and 4.438 mg/kg bw per
day (females)
14 days - (Bauter, 2011)
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SUMMARY OF SAFETY EVALUATIONS
Table 11: Summary of Safety Evaluation by the JECFA (JECFA, 2005b)
FL-no
JECFA-
no
EU Register name Structural formula EU MSDI (a)
US MSDI
(µg/capita per
day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named compound
[(d) or (e)]
EFSA conclusion on
the named
compound
(Procedure steps,
intake estimates,
NOAEL,
genotoxicity)
EFSA conclusion on
the material of
commerce
01.002
1325
1-Isopropyl-4-
methylbenzene
926
472
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.003
1330
Pin-2(10)-ene 1300
759
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.005
1331
Terpinolene 660
70
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.006
1328
alpha-Phellandrene 79
410
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.007
1324
beta-Caryophyllene 330
508
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.009
1323
Camphene 13
28
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
Flavouring Group Evaluation 78 Revision 2
EFSA Journal 2015;13(4):4067 55
Table 11: Summary of Safety Evaluation by the JECFA (JECFA, 2005b)
FL-no
JECFA-
no
EU Register name Structural formula EU MSDI (a)
US MSDI
(µg/capita per
day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named compound
[(d) or (e)]
EFSA conclusion on
the named
compound
(Procedure steps,
intake estimates,
NOAEL,
genotoxicity)
EFSA conclusion on
the material of
commerce
01.010
1333
1-Isopropenyl-4-
methylbenzene
18
0.3
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.016
1336
1,4(8),12-Bisabolatriene 13
10
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.017
1337
Valencene 53
26
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.018
1338
beta-Ocimene
(E)- isomer shown
55
11
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.019
1339
alpha-Terpinene 28
93
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.020
1340
gamma-Terpinene 1200
321
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.024
1345
beta-Bourbonene H
H H
0.012
0.2
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
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Table 11: Summary of Safety Evaluation by the JECFA (JECFA, 2005b)
FL-no
JECFA-
no
EU Register name Structural formula EU MSDI (a)
US MSDI
(µg/capita per
day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named compound
[(d) or (e)]
EFSA conclusion on
the named
compound
(Procedure steps,
intake estimates,
NOAEL,
genotoxicity)
EFSA conclusion on
the material of
commerce
01.026
1347
1(5),7(11)-Guaiadiene
S
S
0.012
3
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.029
1342
delta-3-Carene 290
40
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.040
1343
alpha-Farnesene 0.61
40
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.061
1341
Undeca-1,3,5-triene 0.24
0.2
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.077
1344
1-Methyl-1,3-
cyclohexadiene
0.012
313
Class I
A3: Intake below
threshold
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.004
1329
Pin-2(3)-ene 1800
2444
Class I
A3: Intake above
threshold, A4: Not
endogenous, A5:
Adequate NOAEL
exists
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
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Table 11: Summary of Safety Evaluation by the JECFA (JECFA, 2005b)
FL-no
JECFA-
no
EU Register name Structural formula EU MSDI (a)
US MSDI
(µg/capita per
day)
Class (b)
Evaluation
procedure path (c)
Outcome on the
named compound
[(d) or (e)]
EFSA conclusion on
the named
compound
(Procedure steps,
intake estimates,
NOAEL,
genotoxicity)
EFSA conclusion on
the material of
commerce
01.008
1327
Myrcene 290
153
Class I
A3: Intake above
threshold, A4: Not
endogenous, A5:
Adequate NOAEL
exists
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.045
1326
d-Limonene 34000
12726
Class I
A3: Intake above
threshold, A4: Not
endogenous, A5:
Adequate NOAEL
exists
d No safety concern at
the estimated level of
intake based on the
MSDI approach.
No safety concern at
the estimated level of
intake based on the
MSDI approach.
01.011
1334
4-Methyl-1,1’-biphenyl 0.0085
0.08
Class III
A3: Intake below
threshold
d Genotoxicity data
required.
No longer supported
by Industry (DG
SANCO, 2012).
01.013
1332
Biphenyl 0.00085
0.7
Class III
A3: Intake below
threshold
d Genotoxicity data
required.
No longer supported
by Industry (DG
SANCO, 2012).
01.014
1335
1-Methylnaphthalene 0.73
0.06
Class III
A3: Intake below
threshold
d The Commission has
communicated that
this substance is in
the process of being
deleted from the
Union List (October
2014).
The Commission has
communicated that
this substance is in
the process of being
deleted from the
Union List (October
2014).
(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita per day.
(b): Thresholds of concern: Class I = 1800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
(d): No safety concern based on intake calculated by the MSDI approach of the named compound.
(e): Data must be available on the substance or closely related substances to perform a safety evaluation.
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Table 12: Summary of Safety Evaluation by the EFSA (FGE.25Rev3) (EFSA CEF Panel, in press)
FL-no EU Register name Structural formula EU MSDI (a)
(µg/capita per
day)
Class (b)
Evaluation
procedure path (c)
Outcome on
the named
compound
[(d) or (e)]
Outcome on
the material of
commerce
[(f),( g), or (h)]
Evaluation
remarks
01.027 Bisabola-1,8,12-triene 0.024 Class I
A3: Intake below
threshold
d g
01.028 beta-Bisabolene 2.7 Class I
A3: Intake below
threshold
d f
01.033 2,2-Dimethylhexane 1.2 Class I
A3: Intake below
threshold
d f
01.034 2,4-Dimethylhexane 1.2 Class I
A3: Intake below
threshold
d f
01.038 Dodecane 0.012 Class I
A3: Intake below
threshold
d f
01.039 delta-Elemene 0.012 Class I
A3: Intake below
threshold
d f
01.054 Pentadecane 0.61 Class I
A3: Intake below
threshold
d f
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Table 12: Summary of Safety Evaluation by the EFSA (FGE.25Rev3) (EFSA CEF Panel, in press)
FL-no EU Register name Structural formula EU MSDI (a)
(µg/capita per
day)
Class (b)
Evaluation
procedure path (c)
Outcome on
the named
compound
[(d) or (e)]
Outcome on
the material of
commerce
[(f),( g), or (h)]
Evaluation
remarks
01.057 Tetradecane 0.012 Class I
A3: Intake below
threshold
d f
01.035 2,6-Dimethylocta-2,4,6-
triene
9.1 Class I
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
01.059 4(10)-Thujene 14 Class I
B3: Intake below
threshold, B4:
Adequate NOAEL
exists
d
01.064 cis-3,7-Dimethyl-1,3,6-
octatriene
14 Class I
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
01.070 1-Octene 0.0085 Class I
B3: Intake below
threshold, B4: No
adequate NOAEL
Additional data
required
01.001 Limonene 4000 Class I
A3: Intake above
threshold, A4: Not
endogenous, A5:
Adequate NOAEL
exists
d f
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Table 12: Summary of Safety Evaluation by the EFSA (FGE.25Rev3) (EFSA CEF Panel, in press)
FL-no EU Register name Structural formula EU MSDI (a)
(µg/capita per
day)
Class (b)
Evaluation
procedure path (c)
Outcome on
the named
compound
[(d) or (e)]
Outcome on
the material of
commerce
[(f),( g), or (h)]
Evaluation
remarks
01.046 l-Limonene 2100 Class I
A3: Intake above
threshold, A4: Not
endogenous, A5:
Adequate NOAEL
exists
d f
(a): EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365) = µg/capita per day.
(b):Thresholds of concern: Class I = 1800 µg/person per day, Class II = 540 µg/person per day, Class III = 90 µg/person per day.
(c): Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot.
(d):No safety concern based on intake calculated by the MSDI approach of the named compound.
(e): Data must be available on the substance or closely related substances to perform a safety evaluation.
(f): No safety concern at the estimated level of intake of the material of commerce meeting the specification requirement (based on intake calculated by the MSDI approach).
(g): Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or
information on stereoisomerism.
(h):No conclusion can be drawn due to lack of information on the purity of the material of commerce.
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DOCUMENTATION PROVIDED TO EFSA
1. Bauter MR, 2011. β-Caryophyllene: palatability/toxicity study: a 14-day dietary study in rats. 
Product Safety Labs. Study no. 31085. November 16, 2011. Unpublished report submitted by
EFFA to FLAVIS Secretariat.
2. Bauter MR, 2013a. β-Caryophyllene: a 90-day dietary study in rats. Product Safety Labs. Study 
no. 33328. January 7, 2013. Unpublished report submitted by EFFA to FLAVIS Secretariat.
3. Bauter MR, 2013b. Myrcene: a 90-day dietary study in rats. Product Safety Labs. Study no.
33546. May 20, 2013. Unpublished report submitted by EFFA to FLAVIS Secretariat.
4. DG SANCO (Directorate General for Health and Consumer Affairs), 2012. Information from DG
SANCO 07/02 2012, concerning two lists of 85 and 15 non-supported substances and one list of
30 substances for which no data have been submitted or which are duplicates. FLAVIS.2.23rev1.
5. DG SANTE (Directorate General for Health and Food safety), 2015. Information from DG
SANTE 04 March 2015, concerning the status of substance [FL-no: 01.014] in FGE.78.
6. Di Sotto A, Evandri MG and Mazzanti G, 2008. Antimutagenic and mutagenic activities of some
terpenes in the bacterial reverse mutation assay. Mutation Research 653, 130-133.
7. EFFA (European Flavour and Fragrance Association), 2005. Submission 2004-3. Flavouring
group evaluation of 32 flavouring substances (candidate chemicals) of chemical group 31 (annex I
of 1565/2000/EC) structurally related to aliphatic and aromatic hydrocarbons [FEMA 2004-2]
used as flavouring substances. 24 June 2004. Unpublished report submitted by EFFA to FLAVIS
Secretariat. FLAVIS/8.38.
8. EFFA (European Flavour Association), 2012. Addendum of Additional Data Relevant to the
Flavouring Group Evaluation of the Chemical Group 31 (Annex I of 1565/2000/EC) Aliphatic and
Alicyclic and Aromatic Hydrocarbons [JECFA/WHO FAS 54] Structurally Related to Aliphatic
and Aromatic Hydrocarbons as Evaluated by EFSA in FGE.25Rev2 and FGE.78Rev1. Addendum
to FGE.25Rev2 and FGE.78Rev1. December 2012. FLAVIS/8.176.
9. EFFA (European Flavour Association), 2013. E-mail from EFFA to EFSA and FLAVIS
Secretariat, Danish Food Institute, Technical University of Denmark, dated 30 April 2013.
Information on specifications and stereoisomeric/ positional composition of substances evaluated
in FGE.78Rev2: [FL-no: 01.004, 01.007, 01.008, 01.009, 01.017, 01.018, 01.019, 01.020, 01.024,
01.026, 01.029, 01.040, 01.045, 01.061]. FLAVIS/8.191.
10. EFFA (European Flavour Association), 2014. E-mail from EFFA to FLAVIS Secretariat, Danish
Food Institute, Technical University of Denmark, dated 13 January 2014. Information on
substances in FGE.74Rev3 [FL-no: 12.238, 12.239 and 12.291], FGE.78Rev2 [FL-no: 01.004,
01.018, 01.019, 01.040, 01.045 and 01.061] and FGE.91Rev2 [FL-no: 12.038 and 12.085].
FLAVIS/8.219.
11. EFFA (European Flavour Association), 2015. E-mail from EFFA to FLAVIS Secretariat, Danish
Food Institute, Technical University of Denmark, dated 13 January 2015. Information on
substance [FL-no: 01.004] in FGE.78Rev2.
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12. Flavour Industry, 2010. Unpublished information submitted by Flavour Industry to DG SANCO
and forwarded to EFSA. A-78Rev1/A-25Rev2 [FL-no: 01.008, 01.022, 01.035, 01.047, 01.064].
13. Molina-Jasso D, Álvarez-Gonzáles I and Madrigal-Bujaidar E, 2009. Clastogenicity of β-
caryophyllene in mouse. Biological and Pharmaceutical Bulletin 32(3), 520-522.
14. Zook C and Garlick D, 2013. β-Caryophyllene: a histopathological assessment of the male rat 
kidney. Histo-Scientific Research Laboratories. Product Safety Labs. Study no. 36206. July 30,
2013. Unpublished report submitted by EFFA to FLAVIS Secretariat.
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ABBREVIATIONS
BMDL Benchmark dose level
BW Body Weight
CAS Chemical Abstract Service
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids
CHO Chinese hamster ovary (cells)
CoE Council of Europe
DNA Deoxyribonucleic acid
EFFA European Flavour and Fragrance Association
EPA United States Environmental Protection Agency
EU European Union
FAO Food and Agriculture Organization of the United Nations
FEMA Flavor and Extract Manufacturers Association
FGE Flavouring Group Evaluation
FLAVIS (FL) Flavour Information System (database)
GLP Good Laboratory Practice
GC-MS Gas chromatography-mass spectrometry
ID Identity
I.p. Intraperitoneal
IR Infrared spectroscopy
JECFA Joint FAO/WHO Expert Committee on Food Additives
MSDI Maximised Survey-derived Daily Intake
mTAMDI Modified Theoretical Added Maximum Daily Intake
MOS margin of safety
NCE Normochromatic erythrocyte
NOAEL No observed adverse effect level
NTP National Toxicology Program
OECD Organisation for Economic Co-operation and Development
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PCE Polychromatic erythrocyte
SCE Sister chromatic exchange
SCF Scientific Committee on Food
WHO World Health Organization
